

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12Q 1/68		A2	(11) International Publication Number: WO 00/46405
			(43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/US00/02882		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (Utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 February 2000 (02.02.00)			
(30) Priority Data: 09/243,022 2 February 1999 (02.02.99) US			
(71)(72) Applicant and Inventor: PALSSON, Bernhard [US/US]; 730 Fern Glen, La Jolla, CA 92037 (US).			
(74) Agent: HUNT, Dale, C.; 16th Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).			
		Published Without international search report and to be republished upon receipt of that report.	

(54) Title: METHODS FOR IDENTIFYING DRUG TARGETS BASED ON GENOMIC SEQUENCE DATA

(57) Abstract

This invention provides a computational approach to identifying potential antibacterial drug targets based on a genome sequence and its annotation. Starting from a fully sequenced genome, open reading frame assignments are made which determine the metabolic genotype for the organism. The metabolic genotype, and more specifically its stoichiometric matrix, are analyzed using flux balance analysis to assess the effects of genetic deletions on the fitness of the organism and its ability to produce essential biomolecules required for growth.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHODS FOR IDENTIFYING DRUG TARGETS
BASED ON GENOMIC SEQUENCE DATA**

Background of the Invention

Field of the Invention

5 This invention relates to methods for identifying drug targets based on genomic sequence data. More specifically, this invention relates to systems and methods for determining suitable molecular targets for the directed development of antimicrobial agents.

Description of the Related Art

10 Infectious disease is on a rapid rise and threatens to regain its status as a major health problem. Prior to the discovery of antibiotics in the 1930s, infectious disease was a major cause of death. Further discoveries, development, and mass production of antibiotics throughout the 1940s and 1950s dramatically reduced deaths from microbial infections to a level where they effectively no longer represented a major threat in developed countries.

15 Over the years antibiotics have been liberally prescribed and the strong selection pressure that this represents has led to the emergence of antibiotic resistant strains of many serious human pathogens. In some cases selected antibiotics, such as vancomycin, literally represent the last line of defense against certain pathogenic bacteria such as *Staphylococcus*. The possibility for staphylococci to acquire vancomycin resistance through exchange of genetic material with enterococci, which are commonly resistant to vancomycin, is a serious issue of concern to health care specialists. The pharmaceutical industry continues its search for new antimicrobial compounds, which is a lengthy and tedious, but very important process. The rate of development and introduction of new antibiotics appears to no longer be able to keep up with the evolution of new antibiotic resistant organisms. The rapid emergence of antibiotic resistant organisms threatens to lead to a serious widespread health care concern.

20 The basis of antimicrobial chemotherapy is to selectively kill the microbe with minimal, and ideally no, harm to normal human cells and tissues. Therefore, ideal targets for antibacterial action are biochemical processes that are unique to bacteria, or those that are sufficiently different from the corresponding mammalian processes to allow acceptable discrimination between the two. For effective antibiotic action it is clear that a vital target must exist in the bacterial cell and that the antibiotic be delivered to the target in an active form. Therefore resistance to an antibiotic can arise from: (i) chemical destruction or inactivation of the antibiotic; (ii) alteration of the target site to reduce or eliminate effective antibiotic binding; (iii) blocking antibiotic entry into the cell, or rapid removal from the cell after entry; and (iv) replacing the metabolic step inhibited by the antibiotic.

25 Thus, it is time to fundamentally re-examine the philosophy of microbial killing strategies and develop new paradigms. One such paradigm is a holistic view of cellular metabolism. The identification of "sensitive" metabolic steps in attaining the necessary metabolic flux distributions to support growth and survival that can be attacked to weaken or destroy a microbe, need not be localized to a single biochemical reaction or cellular process. Rather, different cellular targets that need not be intimately related in the metabolic topology could be chosen based on the concerted effect the loss of each of these functions would have on metabolism.

30

35

A similar strategy with viral infections has recently proved successful. It has been shown that "cocktails" of different drugs that target different biochemical processes provide enhanced success in fighting against HIV infection. Such a paradigm shift is possible only if the necessary biological information as well as appropriate methods of rational analysis are available. Recent advances in the field of genomics and bioinformatics, in addition to mathematical modeling, offer the possibility to realize this approach.

At present, the field of microbial genetics is entering a new era where the genomes of several microorganisms are being completely sequenced. It is expected that in a decade, or so, the nucleotide sequences of the genomes of all the major human pathogens will be completely determined. The sequencing of the genomes of pathogens such as *Haemophilus influenzae* has allowed researchers to compare the homology of proteins encoded by the open reading frames (ORFs) with those of *Escherichia coli*, resulting in valuable insight into the *H. influenzae* metabolic features. Similar analyses, such as those performed with *H. influenzae*, will provide details of metabolism spanning the hierarchy of metabolic regulation from bacterial genomes to phenotypes.

These developments provide exciting new opportunities to carry out conceptual experiments *in silico* to analyze different aspects of microbial metabolism and its regulation. Further, the synthesis of whole-cell models is made possible. Such models can account for each and every single metabolic reaction and thus enable the analysis of their role in overall cell function. To implement such analysis, however, a mathematical modeling and simulation framework is needed which can incorporate the extensive metabolic detail but still retain computational tractability. Fortunately, rigorous and tractable mathematical methods have been developed for the required systems analysis of metabolism.

A mathematical approach that is well suited to account for genomic detail and avoid reliance on kinetic complexity has been developed based on well-known stoichiometry of metabolic reactions. This approach is based on metabolic flux balancing in a metabolic steady state. The history of flux balance models for metabolic analyses is relatively short. It has been applied to metabolic networks, and the study of adipocyte metabolism. Acetate secretion from *E. coli* under ATP maximization conditions and ethanol secretion by yeast have also been investigated using this approach.

The complete sequencing of a bacterial genome and ORF assignment provides the information needed to determine the relevant metabolic reactions that constitute metabolism in a particular organism. Thus a flux-balance model can be formulated and several metabolic analyses can be performed to extract metabolic characteristics for a particular organism. The flux balance approach can be easily applied to systematically simulate the effect of single, as well as multiple, gene deletions. This analysis will provide a list of sensitive enzymes that could be potential antimicrobial targets.

The need to consider a new paradigm for dealing with the emerging problem of antibiotic resistant pathogens is a problem of vital importance. The route towards the design of new antimicrobial agents must proceed along directions that are different from those of the past. The rapid growth in bioinformatics has provided a wealth of biochemical and genetic information that can be used to synthesize complete representations of cellular metabolism. These models can be analyzed with relative computational ease through flux-balance models and visual computing

techniques. The ability to analyze the global metabolic network and understand the robustness and sensitivity of its regulation under various growth conditions offers promise in developing novel methods of antimicrobial chemotherapy.

In one example, Pramanik et al. described a stoichiometric model of *E. coli* metabolism using flux-balance modeling techniques (*Stoichiometric Model of Escherichia coli Metabolism: Incorporation of Growth-Rate Dependent Biomass Composition and Mechanistic Energy Requirements*, *Biotechnology and Bioengineering*, Vol. 56, No. 4, November 20, 1997). However, the analytical methods described by Pramanik, et al. can only be used for situations in which biochemical knowledge exists for the reactions occurring within an organism. Pramanik, et al. produced a metabolic model of metabolism for *E. coli* based on biochemical information rather than genomic data since the metabolic genes and related reactions for *E. coli* had already been well studied and characterized. Thus, this method is inapplicable to determining a metabolic model for organisms for which little or no biochemical information on metabolic enzymes and genes is known. It can be envisioned that in the future the only information we may have regarding an emerging pathogen is its genomic sequence. What is needed in the art is a system and method for determining and analyzing the entire metabolic network of organisms whose metabolic reactions have not yet been determined from biochemical assays. The present invention provides such a system.

Summary of the Invention

This invention relates to constructing metabolic genotypes and genome specific stoichiometric matrices from genome annotation data. The functions of the metabolic genes in the target organism are determined by homology searches against databases of genes from similar organisms. Once a potential function is assigned to each metabolic gene of the target organism, the resulting data is analyzed. In one embodiment, each gene is subjected to a flux-balance analysis to assess the effects of genetic deletions on the ability of the target organism to produce essential biomolecules necessary for its growth. Thus, the invention provides a high-throughput computational method to screen for genetic deletions which adversely affect the growth capabilities of fully sequenced organisms.

Embodiments of this invention also provide a computational, as opposed to an experimental, method for the rapid screening of genes and their gene products as potential drug targets to inhibit an organism's growth. This invention utilizes the genome sequence, the annotation data, and the biomass requirements of an organism to construct genomically complete metabolic genotypes and genome-specific stoichiometric matrices. These stoichiometric matrices are analyzed using a flux-balance analysis. This invention describes how to assess the affects of genetic deletions on the fitness and productive capabilities of an organism under given environmental and genetic conditions.

Construction of a genome-specific stoichiometric matrix from genomic annotation data is illustrated along with applying flux-balance analysis to study the properties of the stoichiometric matrix, and hence the metabolic genotype of the organism. By limiting the constraints on various fluxes and altering the environmental inputs to the metabolic network, genetic deletions may be analyzed for their affects on growth. This invention is embodied in a software application that can be used to create the stoichiometric matrix for a fully sequenced and annotated genome. Additionally, the software application can be used to further analyze and manipulate the network so as to predict the ability of an organism to produce biomolecules necessary for growth, thus, essentially simulating a genetic deletion.

Brief Description of the Drawings

Figure 1 is a flow diagram illustrating one procedure for creating metabolic genotypes from genomic sequence data for any organism.

5 Figure 2 is a flow diagram illustrating one procedure for producing *in silico* microbial strains from the metabolic genotypes created by the method of Figure 1, along with additional biochemical and microbiological data.

Figure 3 is a graph illustrating a prediction of genome scale shifts in transcription. The graph shows the different phases of the metabolic response to varying oxygen availability, starting from completely aerobic to completely anaerobic in *E. coli*. The predicted changes in expression pattern between phases II and V are indicated.

Detailed Description of the Preferred Embodiment

10 This invention relates to systems and methods for utilizing genome annotation data to construct a stoichiometric matrix representing most of all of the metabolic reactions that occur within an organism. Using these systems and methods, the properties of this matrix can be studied under conditions simulating genetic deletions in order to predict the affect of a particular gene on the fitness of the organism. Moreover, genes that are vital to the growth of an organism can be found by selectively removing various genes from the stoichiometric matrix and
15 thereafter analyzing whether an organism with this genetic makeup could survive. Analysis of these lethal genetic mutations is useful for identifying potential genetic targets for anti-microbial drugs.

It should be noted that the systems and methods described herein can be implemented on any conventional host computer system, such as those based on Intel® microprocessors and running Microsoft Windows operating systems. Other systems, such as those using the UNIX or LINUX operating system and based on IBM®, DEC® or
20 Motorola® microprocessors are also contemplated. The systems and methods described herein can also be implemented to run on client-server systems and wide-area networks, such as the Internet.

Software to implement the system can be written in any well-known computer language, such as Java, C, C++ , Visual Basic, FORTRAN or COBOL and compiled using any well-known compatible compiler.

25 The software of the invention normally runs from instructions stored in a memory on the host computer system. Such a memory can be a hard disk, Random Access Memory, Read Only Memory and Flash Memory. Other types of memories are also contemplated to function within the scope of the invention.

A process 10 for producing metabolic genotypes from an organism is shown in Figure 1. Beginning at a start state 12, the process 10 then moves to a state 14 to obtain the genomic DNA sequence of an organism. The nucleotide sequence of the genomic DNA can be rapidly determined for an organism with a genome size on the order of
30 a few million base pairs. One method for obtaining the nucleotide sequences in a genome is through commercial gene databases. Many gene sequences are available on-line through a number of sites (see, for example, www.tigr.org) and can easily be downloaded from the Internet. Currently, there are 16 microbial genomes that have been fully sequenced and are publicly available, with countless others held in proprietary databases. It is expected that a number of other organisms, including pathogenic organisms will be found in nature for which little experimental information, except for
35 its genome sequence, will be available.

Once the nucleotide sequence of the entire genomic DNA in the target organism has been obtained at state 14, the coding regions, also known as open reading frames, are determined at a state 16. Using existing computer algorithms, the location of open reading frames that encode genes from within the genome can be determined. For example, to identify the proper location, strand, and reading frame of an open reading frame one can perform a gene search by signal (promoters, ribosomal binding sites, etc.) or by content (positional base frequencies, codon preference). Computer programs for determining open reading frames are available, for example, by the University of Wisconsin Genetics Computer Group and the National Center for Biotechnology Information.

After the location of the open reading frames have been determined at state 16, the process 10 moves to state 18 to assign a function to the protein encoded by the open reading frame. The discovery that an open reading frame or gene has sequence homology to a gene coding for a protein of known function, or family of proteins of known function, can provide the first clues about the gene and its related protein's function. After the locations of the open reading frames have been determined in the genomic DNA from the target organism, well-established algorithms (i.e. the Basic Local Alignment Search Tool (BLAST) and the FAST family of programs can be used to determine the extent of similarity between a given sequence and gene/protein sequences deposited in worldwide genetic databases. If a coding region from a gene in the target organism is homologous to a gene within one of the sequence databases, the open reading frame is assigned a function similar to the homologously matched gene. Thus, the functions of nearly the entire gene complement or genotype of an organism can be determined so long as homologous genes have already been discovered.

All of the genes involved in metabolic reactions and functions in a cell comprise only a subset of the genotype. This subset of genes is referred to as the metabolic genotype of a particular organism. Thus, the metabolic genotype of an organism includes most or all of the genes involved in the organism's metabolism. The gene products produced from the set of metabolic genes in the metabolic genotype carry out all or most of the enzymatic reactions and transport reactions known to occur within the target organism as determined from the genomic sequence.

To begin the selection of this subset of genes, one can simply search through the list of functional gene assignments from state 18 to find genes involved in cellular metabolism. This would include genes involved in central metabolism, amino acid metabolism, nucleotide metabolism, fatty acid and lipid metabolism, carbohydrate assimilation, vitamin and cofactor biosynthesis, energy and redox generation, etc. This subset is generated at a state 20. The process 10 of determining metabolic genotype of the target organism from genomic data then terminates at an end stage 22.

Referring now to Figure 2, the process 50 of producing a computer model of an organism. This process is also known as producing *in silico* microbial strains. The process 50 begins at a start state 52 (same as end state 22 of process 10) and then moves to a state 54 wherein biochemical information is gathered for the reactions performed by each metabolic gene product for each of the genes in the metabolic genotype determined from process 10.

For each gene in the metabolic genotype, the substrates and products, as well as the stoichiometry of any and all reactions performed by the gene product of each gene can be determined by reference to the biochemical

literature. This includes information regarding the irreversible or reversible nature of the reactions. The stoichiometry of each reaction provides the molecular ratios in which reactants are converted into products.

Potentially, there may still remain a few reactions in cellular metabolism which are known to occur from *in vitro* assays and experimental data. These would include well characterized reactions for which a gene or protein has yet to be identified, or was unidentified from the genome sequencing and functional assignment of state 14 and 18. This would also include the transport of metabolites into or out of the cell by uncharacterized genes related to transport. Thus one reason for the missing gene information may be due to a lack of characterization of the actual gene that performs a known biochemical conversion. Therefore upon careful review of existing biochemical literature and available experimental data, additional metabolic reactions can be added to the list of metabolic reactions determined from the metabolic genotype from state 54 at a state 56. This would include information regarding the substrates, products, reversibility/irreversibility, and stoichiometry of the reactions.

All of the information obtained at states 54 and 56 regarding reactions and their stoichiometry can be represented in a matrix format typically referred to as a stoichiometric matrix. Each column in the matrix corresponds to a given reaction or flux, and each row corresponds to the different metabolites involved in the given reaction/flux. Reversible reactions may either be represented as one reaction that operates in both the forward and reverse direction or be decomposed into one forward reaction and one backward reaction in which case all fluxes can only take on positive values. Thus, a given position in the matrix describes the stoichiometric participation of a metabolite (listed in the given row) in a particular flux of interest (listed in the given column). Together all of the columns of the genome specific stoichiometric matrix represent all of the chemical conversions and cellular transport processes that are determined to be present in the organism. This includes all internal fluxes and so called exchange fluxes operating within the metabolic network. Thus, the process 50 moves to a state 58 in order to formulate all of the cellular reactions together in a genome specific stoichiometric matrix. The resulting genome specific stoichiometric matrix is a fundamental representation of a genomically and biochemically defined genotype.

After the genome specific stoichiometric matrix is defined at state 58, the metabolic demands placed on the organism are calculated. The metabolic demands can be readily determined from the dry weight composition of the cell. In the case of well-studied organisms such as *Escherichia coli* and *Bacillus subtilis*, the dry weight composition is available in the published literature. However, in some cases it will be necessary to experimentally determine the dry weight composition of the cell for the organism in question. This can be accomplished with varying degrees of accuracy. The first attempt would measure the RNA, DNA, protein, and lipid fractions of the cell. A more detailed analysis would also provide the specific fraction of nucleotides, amino acids, etc. The process 50 moves to state 60 for the determination of the biomass composition of the target organism.

The process 50 then moves to state 62 to perform several experiments that determine the uptake rates and maintenance requirements for the organism. Microbiological experiments can be carried out to determine the uptake rates for many of the metabolites that are transported into the cell. The uptake rate is determined by measuring the depletion of the substrate from the growth media. The measurement of the biomass at each point is also required, in order to determine the uptake rate per unit biomass. The maintenance requirements can be determined from a

chemostat experiment. The glucose uptake rate is plotted versus the growth rate, and the y-intercept is interpreted as the non-growth associated maintenance requirements. The growth associated maintenance requirements are determined by fitting the model results to the experimentally determined points in the growth rate versus glucose uptake rate plot.

5 Next, the process 50 moves to a state 64 wherein information regarding the metabolic demands and uptake rates obtained at state 62 are combined with the genome specific stoichiometric matrix of step 8 together fully define the metabolic system using flux balance analysis (FBA). This is an approach well suited to account for genomic detail as it has been developed based on the well-known stoichiometry of metabolic reactions.

10 The time constants characterizing metabolic transients and/or metabolic reactions are typically very rapid, on the order of milli-seconds to seconds, compared to the time constants of cell growth on the order of hours to days. Thus, the transient mass balances can be simplified to only consider the steady state behavior. Eliminating the time derivatives obtained from dynamic mass balances around every metabolite in the metabolic system, yields the system of linear equations represented in matrix notation,

$$S \cdot v = 0 \qquad \text{Equation 1}$$

15 where S refers to the stoichiometric matrix of the system, and v is the flux vector. This equation simply states that over long times, the formation fluxes of a metabolite must be balanced by the degradation fluxes. Otherwise, significant amounts of the metabolite will accumulate inside the metabolic network. Applying equation 1 to our system we let S now represent the genome specific stoichiometric matrix

20 To determine the metabolic capabilities of a defined metabolic genotype Equation 1 is solved for the metabolic fluxes and the internal metabolic reactions, v , while imposing constraints on the activity of these fluxes. Typically the number of metabolic fluxes is greater than the number of mass balances (i.e., $m > n$) resulting in a plurality of feasible flux distributions that satisfy Equation 1 and any constraints placed on the fluxes of the system. This range of solutions is indicative of the flexibility in the flux distributions that can be achieved with a given set of metabolic reactions. The solutions to Equation 1 lie in a restricted region. This subspace defines the capabilities of the *metabolic genotype* of a given organism, since the allowable solutions that satisfy Equation 1 and any constraints placed on the fluxes of the system define all the metabolic flux distributions that can be achieved with a particular set of metabolic genes.

25 The particular utilization of the metabolic genotype can be defined as the *metabolic phenotype* that is expressed under those particular conditions. Objectives for metabolic function can be chosen to explore the 'best' use of the metabolic network within a given metabolic genotype. The solution to equation 1 can be formulated as a linear programming problem, in which the flux distribution that minimizes a particular objective is found. Mathematically, this optimization can be stated as;

$$\text{Minimize } Z \qquad \text{Equation 2}$$

$$35 \qquad \text{where } Z = \sum c_i \cdot v_i = \langle c \cdot v \rangle \qquad \text{Equation 3}$$

where Z is the objective which is represented as a linear combination of metabolic fluxes v_i . The optimization can also be stated as the equivalent maximization problem; i.e. by changing the sign on Z .

This general representation of Z enables the formulation of a number of diverse objectives. These objectives can be design objectives for a strain, exploitation of the metabolic capabilities of a genotype, or physiologically meaningful objective functions, such as maximum cellular growth. For this application, growth is to be defined in terms of biosynthetic requirements based on literature values of biomass composition or experimentally determined values such as those obtained from state 60. Thus, we can define biomass generation as an additional reaction flux draining intermediate metabolites in the appropriate ratios and represented as an objective function Z . In addition to draining intermediate metabolites this reaction flux can be formed to utilize energy molecules such as ATP, NADH and NADPH so as to incorporate any maintenance requirement that must be met. This new reaction flux then becomes another constraint/balance equation that the system must satisfy as the objective function. It is analogous to adding an addition column to the stoichiometric matrix of Equation 1 to represent such a flux to describe the production demands placed on the metabolic system. Setting this new flux as the objective function and asking the system to maximize the value of this flux for a given set of constraints on all the other fluxes is then a method to simulate the growth of the organism.

Using linear programming, additional constraints can be placed on the value of any of the fluxes in the metabolic network.

$$\beta_i \leq v_i \leq \alpha_i \quad \text{Equation 4}$$

These constraints could be representative of a maximum allowable flux through a given reaction, possibly resulting from a limited amount of an enzyme present in which case the value for α_i would take on a finite value. These constraints could also be used to include the knowledge of the minimum flux through a certain metabolic reaction in which case the value for β_i would take on a finite value. Additionally, if one chooses to leave certain reversible reactions or transport fluxes to operate in a forward and reverse manner the flux may remain unconstrained by setting β_i to negative infinity and α_i to positive infinity. If reactions proceed only in the forward reaction β_i is set to zero while α_i is set to positive infinity. As an example, to simulate the event of a genetic deletion the flux through all of the corresponding metabolic reactions related to the gene in question are reduced to zero by setting β_i and α_i to be zero in Equation 4. Based on the *in vivo* environment where the bacteria lives one can determine the metabolic resources available to the cell for biosynthesis of essentially molecules for biomass. Allowing the corresponding transport fluxes to be active provides the *in silico* bacteria with inputs and outputs for substrates and by-products produces by the metabolic network. Therefore as an example, if one wished to simulate the absence of a particular growth substrate one simply constrains the corresponding transport fluxes allowing the metabolite to enter the cell to be zero by allowing β_i and α_i to be zero in Equation 4. On the other hand if a substrate is only allowed to enter or exit the cell via transport mechanisms, the corresponding fluxes can be properly constrained to reflect this scenario.

Together the linear programming representation of the genome-specific stoichiometric matrix as in Equation 1 along with any general constraints placed on the fluxes in the system, and any of the possible objective functions

completes the formulation of the *in silico* bacterial strain. The *in silico* strain can then be used to study theoretical metabolic capabilities by simulating any number of conditions and generating flux distributions through the use of linear programming. The process 50 of formulating the *in silico* strain and simulating its behavior using linear programming techniques terminates at an end state 66.

5 Thus, by adding or removing constraints on various fluxes in the network it is possible to (1) simulate a genetic deletion event and (2) simulate or accurately provide the network with the metabolic resources present in its *in vivo* environment. Using flux balance analysis it is possible to determine the affects of the removal or addition of particular genes and their associated reactions to the composition of the metabolic genotype on the range of possible metabolic phenotypes. If the removal/deletion does not allow the metabolic network to produce necessary precursors for growth, and the cell can not obtain these precursors from its environment, the deletion(s) has the potential as an antimicrobial drug target. Thus by adjusting the constraints and defining the objective function we can explore the capabilities of the metabolic genotype using linear programming to optimize the flux distribution through the metabolic network. This creates what we will refer to as an *in silico* bacterial strain capable of being studied and manipulated to analyze, interpret, and predict the genotype-phenotype relationship. It can be applied to assess the affects of incremental changes in the genotype or changing environmental conditions, and provide a tool for computer aided experimental design. It should be realized that other types of organisms can similarly be represented *in silico* and still be within the scope of the invention.

20 The construction of a genome specific stoichiometric matrix and *in silico* microbial strains can also be applied to the area of signal transduction. The components of signaling networks can be identified within a genome and used to construct a content matrix that can be further analyzed using various techniques to be determined in the future.

Example 1: E. coli metabolic genotype and in silico model

25 Using the methods disclosed in Figures 1 and 2, an *in silico* strain of *Escherichia coli* K-12 has been constructed and represents the first such strain of a bacteria largely generated from annotated sequence data and from biochemical information. The genetic sequence and open reading frame identifications and assignments are readily available from a number of on-line locations (ex: www.tigr.org). For this example we obtained the annotated sequence from the following website for the *E. coli* Genome Project at the University of Wisconsin (<http://www.genetics.wisc.edu/>). Details regarding the actual sequencing and annotation of the sequence can be found at that site. From the genome annotation data the subset of genes involved in cellular metabolism was determined as described above in Figure 1, state 20, comprising the metabolic genotype of the particular strain of *E. coli*.

30 Through detailed analysis of the published biochemical literature on *E. coli* we determined (1) all of the reactions associated with the genes in the metabolic genotype and (2) any additional reactions known to occur from biochemical data which were not represented by the genes in the metabolic genotype. This provided all of the necessary information to construct the genome specific stoichiometric matrix for *E. coli* K-12.

35 Briefly, the *E. coli* K-12 bacterial metabolic genotype and more specifically the genome specific stoichiometric matrix contains 731 metabolic processes that influence 436 metabolites (dimensions of the genome specific stoichiometric matrix are 436 x 731). There are 80 reactions present in the genome specific stoichiometric

matrix that do not have a genetic assignment in the annotated genome, but are known to be present from biochemical data. The genes contained within this metabolic genotype are shown in Table 1 along with the corresponding reactions they carry out.

Because *E. coli* is arguably the best studied organism, it was possible to determine the uptake rates and maintenance requirements (state 62 of Figure 2) by reference to the published literature. This *in silico* strain accounts for the metabolic capabilities of *E. coli*. It includes membrane transport processes, the central catabolic pathways, utilization of alternative carbon sources and the biosynthetic pathways that generate all the components of the biomass. In the case of *E. coli* K-12, we can call upon the wealth of data on overall metabolic behavior and detailed biochemical information about the *in vivo* genotype to which we can compare the behavior of the *in silico* strain. One utility of FBA is the ability to learn about the physiology of the particular organism and explore its metabolic capabilities without any specific biochemical data. This ability is important considering possible future scenarios in which the only data that we may have for a newly discovered bacterium (perhaps pathogenic) could be its genome sequence.

Example 2: in silico deletion analysis for *E. coli* to find antimicrobial targets

Using the *in silico* strain constructed in Example 1, the effect of individual deletions of all the enzymes in central metabolism can be examined *in silico*. For the analysis to determine sensitive linkages in the metabolic network of *E. coli*, the objective function utilized is the maximization of the biomass yield. This is defined as a flux draining the necessary biosynthetic precursors in the appropriate ratios. This flux is defined as the biomass composition, which can be determined from the literature. See Neidhardt et. al., *Escherichia coli and Salmonella: Cellular and Molecular Biology*, Second Edition, ASM Press, Washington D.C., 1996. Thus, the objective function is the maximization of a single flux, this biosynthetic flux.

Constraints are placed on the network to account for the availability of substrates for the growth of *E. coli*. In the initial deletion analysis, growth was simulated in an aerobic glucose minimal media culture. Therefore, the constraints are set to allow for the components included in the media to be taken up. The specific uptake rate can be included if the value is known, otherwise, an unlimited supply can be provided. The uptake rate of glucose and oxygen have been determined for *E. coli* (Neidhardt et. al., *Escherichia coli and Salmonella: Cellular and Molecular Biology*, Second Edition, ASM Press, Washington D.C., 1996. Therefore, these values are included in the analysis. The uptake rate for phosphate, sulfur, and nitrogen source is not precisely known, so constraints on the fluxes for the uptake of these important substrates is not included, and the metabolic network is allowed to take up any required amount of these substrates.

The results showed that a high degree of redundancy exists in central intermediary metabolism during growth in glucose minimal media, which is related to the interconnectivity of the metabolic reactions. Only a few metabolic functions were found to be essential such that their loss removes the capability of cellular growth on glucose. For growth on glucose, the essential gene products are involved in the 3-carbon stage of glycolysis, three reactions of the

TCA cycle, and several points within the PPP. Deletions in the 6-carbon stage of glycolysis result in a reduced ability to support growth due to the diversion of additional flux through the PPP.

The results from the gene deletion study can be directly compared with growth data from mutants. The growth characteristics of a series of *E. coli* mutants on several different carbon sources were examined (80 cases were determined from the literature), and compared to the *in silico* deletion results (Table 2). The majority (73 of 80 cases or 91%) of the mutant experimental observations are consistent with the predictions of the *in silico* study. The results from the *in silico* gene deletion analysis are thus consistent with experimental observations.

Example 3: Prediction of genome scale shifts in gene expression

Flux based analysis can be used to predict metabolic phenotypes under different growth conditions, such as substrate and oxygen availability. The relation between the flux value and the gene expression levels is non-linear, resulting in bifurcations and multiple steady states. However, FBA can give qualitative (on/off) information as well as the relative importance of gene products under a given condition. Based on the magnitude of the metabolic fluxes, qualitative assessment of gene expression can be inferred.

Figure 3a shows the five phases of distinct metabolic behavior of *E. Coli* in response to varying oxygen availability, going from completely anaerobic (phase I) to completely aerobic (phase V). Figures 3b and 3c display lists of the genes that are predicted to be induced or repressed upon the shift from aerobic growth (phase V) to nearly complete anaerobic growth (phase II). The numerical values shown in Figures 3b and 3c are the fold change in the magnitude of the fluxes calculated for each of the listed enzymes.

For this example, the objective of maximization of biomass yield is utilized (as described above). The constraints on the system are also set accordingly (as described above). However, in this example, a change in the availability of a key substrate is leading to changes in the metabolic behavior. The change in the parameter is reflected as a change in the uptake flux. Therefore, the maximal allowable oxygen uptake rate is changed to generate this data. The figure demonstrates how several fluxes in the metabolic network will change as the oxygen uptake flux is continuously decreased. Therefore, the constraints on the fluxes is identical to what is described in the previous section, however, the oxygen uptake rate is set to coincide with the point in the diagram.

Corresponding experimental data sets are now becoming available. Using high-density oligonucleotide arrays the expression levels of nearly every gene in *Saccharomyces cerevisiae* can now be analyzed under various growth conditions. From these studies it was shown that nearly 90% of all yeast mRNAs are present in growth on rich and minimal media, while a large number of mRNAs were shown to be differentially expressed under these two conditions. Another recent article shows how the metabolic and genetic control of gene expression can be studied on a genomic scale using DNA microarray technology (*Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale, Science*, Vol. 278, October 24, 1997). The temporal changes in genetic expression profiles that occur during the diauxic shift in *S. cerevisiae* were observed for every known expressed sequence tag (EST) in this genome. As shown above, FBA can be used to qualitatively simulate shifts in metabolic genotype expression patterns due to alterations in

growth environments. Thus, FBA can serve to complement current studies in metabolic gene expression, by providing a fundamental approach to analyze, interpret, and predict the data from such experiments.

Example 4: Design of defined media

An important economic consideration in large-scale bioprocesses is optimal medium formulation. FBA can be used to design such media. Following the approach defined above, a flux-balance model for the first completely sequenced free living organism, *Haemophilus influenzae*, has been generated. One application of this model is to predict a minimal defined media. It was found that *H. influenzae* can grow on the minimal defined medium as determined from the ORF assignments and predicted using FBA. Simulated bacterial growth was predicted using the following defined media: fructose, arginine, cysteine, glutamate, putrescine, spermidine, thiamin, NAD, tetrapyrrole, pantothenate, ammonia, phosphate. This predicted minimal medium was compared to the previously published defined media and was found to differ in only one compound, inosine. It is known that inosine is not required for growth, however it does serve to enhance growth. Again the *in silico* results obtained were consistent with published *in vivo* research. These results provide confidence in the use of this type of approach for the design of defined media for organisms in which there currently does not exist a defined media.

While particular embodiments of the invention have been described in detail, it will be apparent to those skilled in the art that these embodiments are exemplary rather than limiting, and the true scope of the invention is defined by the claims that follow.

Table 1

The genes included in the *E. coli* metabolic genotype along with corresponding enzymes and reactions that comprise the genome specific stoichiometric matrix. The final column indicates the presence/absence of the gene (as the number of copies) in the *E. coli* genome. Thus the presence of a gene in the *E. coli* genome indicates that the gene is part of the metabolic genotype. Reactions/Genes not present in the genome are those gathered at state 56 in Figure 2 and together with the reactions of the genes in the metabolic genotype form the columns of the genome specific stoichiometric matrix.

Enzyme	Gene	Reaction	<i>E. coli</i> genome
Glucokinase	<i>g/k</i>	GLC + ATP \rightarrow G6P + ADP	1
Glucokinase	<i>g/k</i>	bDGLC + ATP \rightarrow bDGGP + ADP	1
Phosphoglucose isomerase	<i>pgi</i>	G6P \leftrightarrow F6P	1
Phosphoglucose isomerase	<i>pgi</i>	bDGGP \leftrightarrow G6P	1
Phosphoglucose isomerase	<i>pgi</i>	bDGGP \leftrightarrow F6P	1
Aldose 1-epimerase	<i>galM</i>	bDGLC \leftrightarrow GLC	1
Glucose-1-phosphatase	<i>agp</i>	G1P \rightarrow GLC + PI	1
Phosphofructokinase	<i>pfkA</i>	F6P + ATP \rightarrow FDP + ADP	1
Phosphofructokinase B	<i>pfkB</i>	F6P + ATP \rightarrow FDP + ADP	1
Fructose-1,6-bisphosphatase	<i>fbp</i>	FDP \rightarrow F6P + PI	1
Fructose-1,6-bisphosphatase aldolase	<i>fba</i>	FDP \leftrightarrow T3P1 + T3P2	2
Triosphosphate isomerase	<i>tpiA</i>	T3P1 \leftrightarrow T3P2	1
Methylglyoxal synthase	<i>mgx4</i>	T3P2 \rightarrow MTHGXL + PI	0
Glyceraldehyde-3-phosphate dehydrogenase-A complex	<i>gapA</i>	T3P1 + PI + NAD \leftrightarrow NADH + 13PDG	1
Glyceraldehyde-3-phosphate dehydrogenase-C complex	<i>gapC1C2</i>	T3P1 + PI + NAD \leftrightarrow NADH + 13PDG	2

Enzyme	Gene	Reaction	E. coli genome
Phosphoglycerate kinase	<i>pgk</i>	13PDG + ADP \leftrightarrow 3PG + ATP	1
Phosphoglycerate mutase 1	<i>gpmA</i>	3PG \leftrightarrow 2PG	1
Phosphoglycerate mutase 2	<i>gpmB</i>	3PG \leftrightarrow 2PG	1
Enolase	<i>eno</i>	2PG \leftrightarrow PEP	1
Phosphoenolpyruvate synthase	<i>ppsA</i>	PYR + ATP \rightarrow PEP + AMP + PI	1
Pyruvate Kinase II	<i>pykA</i>	PEP + ADP \rightarrow PYR + ATP	1
Pyruvate Kinase I	<i>pykF</i>	PEP + ADP \rightarrow PYR + ATP	1
Pyruvate dehydrogenase	<i>lpdA, aceEF</i>	PYR + COA + NAD \rightarrow NADH + CO ₂ + ACCOA	3
Glucose-1-phosphate adenylyltransferase	<i>glgC</i>	ATP + G1P \rightarrow ADPGLC + PPI	1
Glycogen synthase	<i>glgA</i>	ADPGLC \rightarrow ADP + GLYCOGEN	1
Glycogen phosphorylase	<i>glgP</i>	GLYCOGEN + PI \rightarrow G1P	1
Maltodextrin phosphorylase	<i>malP</i>	GLYCOGEN + PI \rightarrow G1P	1
Glucose 6-phosphate-1-dehydrogenase	<i>zwf</i>	G6P + NADP \leftrightarrow D6PGL + NADPH	1
6-Phosphogluconolactonase	<i>pgl</i>	D6PGL \rightarrow D6PGC	0
6-Phosphogluconate dehydrogenase (decarboxylating)	<i>gnd</i>	D6PGC + NADP \rightarrow NADPH + CO ₂ + RL5P	1
Ribose-5-phosphate isomerase A	<i>rpiA</i>	RL5P \leftrightarrow R5P	1
Ribose-5-phosphate isomerase B	<i>rpiB</i>	RL5P \leftrightarrow R5P	1
Ribulose phosphate 3-epimerase	<i>rpe</i>	RL5P \leftrightarrow X5P	1
Transketolase I	<i>tktA</i>	R5P + X5P \leftrightarrow T3P1 + S7P	1
Transketolase II	<i>tktB</i>	R5P + X5P \leftrightarrow T3P1 + S7P	1
Transketolase I	<i>tktA</i>	X5P + E4P \leftrightarrow F6P + T3P1	1

Enzyme	Gene	Reaction	E. coli genome
Transketolase II	<i>tktB</i>	X5P + E4P <-> F6P + T3P1	1
Transaldolase B	<i>talB</i>	T3P1 + S7P <-> E4P + F6P	1
Phosphoglucuronate dehydratase	<i>edd</i>	D6PGC -> 2KD6PG	1
2-Keto-3-deoxy-6-phosphoglucuronate aldolase	<i>eda</i>	2KD6PG -> T3P1 + PYR	1
Citrate synthase	<i>glcA</i>	ACCOA + OA -> COA + CIT	1
Aconitase A	<i>acnA</i>	CIT <-> ICIT	1
Aconitase B	<i>acnB</i>	CIT <-> ICIT	1
Isocitrate dehydrogenase	<i>icdA</i>	ICIT + NADP <-> CO2 + NADPH + AKG	1
2-Ketoglutarate dehydrogenase	<i>sucAB, lpdA</i>	AKG + NAD + COA -> CO2 + NADH + SUCCOA	3
Succinyl-CoA synthetase	<i>sucCD</i>	SUCCOA + AOP + PI <-> ATP + COA + SUCC	2
Succinate dehydrogenase	<i>sdhABCD</i>	SUCC + FAD -> FADH + FUM	4
Fumarate reductase	<i>frdABCD</i>	FUM + FADH -> SUCC + FAD	4
Fumarase A	<i>fumA</i>	FUM <-> MAL	1
Fumarase B	<i>fumB</i>	FUM <-> MAL	1
Fumarase C	<i>fumC</i>	FUM <-> MAL	1
Malate dehydrogenase	<i>mdh</i>	MAL + NAD <-> NADH + OA	1
D-Lactate dehydrogenase 1	<i>ldd</i>	PYR + NADH <-> NAD + LAC	1
D-Lactate dehydrogenase 2	<i>ldhA</i>	PYR + NADH <-> NAD + LAC	1
Acetaldehyde dehydrogenase	<i>adhE</i>	ACCOA + 2 NADH <-> ETH + 2 NAD + COA	1
Pyruvate formate lyase 1	<i>pflAB</i>	PYR + COA -> ACCOA + FOR	2
Pyruvate formate lyase 2	<i>pflCD</i>	PYR + COA -> ACCOA + FOR	2

Enzyme	Gene	Reaction	E. coli genome
Formate hydrogen lyase	<i>fdhF, hycBEEG</i>	FOR → CO ₂	5
Phosphotransacetylase	<i>pta</i>	ACCOA + PI <→ ACTP + COA	1
Acetate kinase A	<i>ackA</i>	ACTP + ADP <→ ATP + AC	1
GAR transformylase I	<i>purT</i>	ACTP + ADP <→ ATP + AC	1
Acetyl-CoA synthetase	<i>acs</i>	ATP + AC + COA → AMP + PPI + ACCOA	1
Phosphoenolpyruvate carboxykinase	<i>pcckA</i>	OA + ATP → PEP + CO ₂ + ADP	1
Phosphoenolpyruvate carboxylase	<i>ppc</i>	PEP + CO ₂ → OA + PI	1
Malic enzyme (NADP)	<i>maeB</i>	MAL + NAOP → CO ₂ + NAOPH + PYR	0
Malic enzyme (NAD)	<i>sfcA</i>	MAL + NAD → CO ₂ + NADH + PYR	1
Isocitrate lyase	<i>aceA</i>	ICIT → GLX + SUCC	1
Malate synthase A	<i>aceB</i>	ACCOA + GLX → COA + MAL	1
Malate synthase G	<i>glcB</i>	ACCOA + GLX → COA + MAL	1
Inorganic pyrophosphatase	<i>ppa</i>	PPI → 2 PI	1
NAOH dehydrogenase II	<i>ndh</i>	NADH + Q → NAD + QH ₂	1
NAOH dehydrogenase I	<i>nuoABEFGHJKLMN</i>	NADH + Q → NAD + QH ₂ + 3.5 HEXT	1
Formate dehydrogenase-N	<i>fdnGHI</i>	FOR + Q → QH ₂ + CO ₂ + 2 HEXT	3
Formate dehydrogenase-O	<i>fdhHIG</i>	FOR + Q → QH ₂ + CO ₂ + 2 HEXT	3
Formate dehydrogenase	<i>fdhF</i>	FOR + Q → QH ₂ + CO ₂ + 2 HEXT	1
Pyruvate oxidase	<i>poxB</i>	PYR + Q → AC + CO ₂ + QH ₂	1
Glycerol-3-phosphate dehydrogenase (aerobic)	<i>glpD</i>	GL3P + Q → T3P ₂ + QH ₂	1
Glycerol-3-phosphate dehydrogenase (anaerobic)	<i>glpABC</i>	GL3P + Q → T3P ₂ + QH ₂	3

Enzyme	Gene	Reaction	E. coli genome
Cytochrome oxidase bo3	<i>cyoABCD, cycBC, cydAB</i>	$\text{QH}_2 + 5 \text{ O}_2 \rightarrow \text{Q} + 2.5 \text{ H}_2\text{O}$	6
Cytochrome oxidase bd	<i>cydABCD, oppBC, cycBC</i>	$\text{QH}_2 + 5 \text{ O}_2 \rightarrow \text{Q} + 2 \text{ H}_2\text{O}$	6
Succinate dehydrogenase complex	<i>sdhABCD</i>	$\text{FADH} + \text{Q} \rightarrow \text{FAD} + \text{QH}_2$	4
Thioredoxin reductase	<i>trxR</i>	$\text{OTHIO} + \text{NADPH} \rightarrow \text{NADP} + \text{RTHIO}$	1
Pyridine nucleotide transhydrogenase	<i>pntAB</i>	$\text{NADPH} + \text{NAD} \rightarrow \text{NADP} + \text{NADH}$	2
Pyridine nucleotide transhydrogenase	<i>pntAB</i>	$\text{NADP} + \text{NADH} + 2 \text{ H}_2\text{O} \rightarrow \text{NADPH} + \text{NAD}$	2
Hydrogenase 1	<i>hyaABC</i>	$2 \text{ Q} + 2 \text{ H}_2\text{O} \rightarrow 2 \text{ QH}_2 + \text{H}_2$	3
Hydrogenase 2	<i>hybAC</i>	$2 \text{ Q} + 2 \text{ H}_2\text{O} \rightarrow 2 \text{ QH}_2 + \text{H}_2$	2
Hydrogenase 3	<i>hycFGE</i>	$2 \text{ Q} + 2 \text{ H}_2\text{O} \rightarrow 2 \text{ QH}_2 + \text{H}_2$	4
FOF1-ATPase	<i>atpABCD, EFGHI</i>	$\text{ATP} \rightarrow \text{ADP} + \text{P}_i$	9
Alpha-galactosidase (melibiase)	<i>melA</i>	$\text{MELI} \rightarrow \text{GLC} + \text{GLAC}$	1
Galactokinase	<i>galK</i>	$\text{GLAC} + \text{ATP} \rightarrow \text{GALIP} + \text{ADP}$	1
Galactose-1-phosphate uridylyltransferase	<i>galT</i>	$\text{GALIP} + \text{UDP} \rightarrow \text{G1P} + \text{UDPGAL}$	1
UDP-glucose 4-epimerase	<i>galE</i>	$\text{UDPGAL} \rightarrow \text{UDPG}$	1
UDP-glucose-1-phosphate uridylyltransferase	<i>galU</i>	$\text{G1P} + \text{UTP} \rightarrow \text{UDPG} + \text{PP}_i$	1
Phosphoglucosylmutase	<i>pgm</i>	$\text{G1P} \rightarrow \text{G6P}$	1
Periplasmic beta-glucosidase precursor	<i>bgIX</i>	$\text{LCTS} \rightarrow \text{GLC} + \text{GLAC}$	1
Beta-galactosidase (LACTase)	<i>lacZ</i>	$\text{LCTS} \rightarrow \text{GLC} + \text{GLAC}$	1
Trehalose-6-phosphate hydrolase	<i>treC</i>	$\text{TRE6P} \rightarrow \text{bDGGP} + \text{GLC}$	1
Beta-fructofuranosidase		$\text{SUC6P} \rightarrow \text{G6P} + \text{FRU}$	0
1-Phosphofructokinase (Fructose 1-phosphate kinase)	<i>fruK</i>	$\text{F1P} + \text{ATP} \rightarrow \text{FDP} + \text{ADP}$	1

Enzyme	Gene	Reaction	E. coli genome
Xylose isomerase	<i>xyIA</i>	FRU → GLC	1
Phosphomannomutase	<i>cpsG</i>	MANGP <→ MAN1P	1
Mannose-6-phosphate isomerase	<i>manA</i>	MAN1P <→ FBP	1
N-Acetylglucosamine-6-phosphate deacetylase	<i>nagA</i>	NAGP → G6P + AC	1
Glucosamine-6-phosphate deaminase	<i>nagB</i>	G6P → FBP + NH ₃	1
N-Acetylneuraminatase lyase	<i>nana</i>	SLA → PYR + NAMAN	1
L-Fucose isomerase	<i>fucI</i>	FUC <→ FCL	1
L-Fuculokinase	<i>fucK</i>	FCL + ATP → FCL1P + ADP	1
L-Fucose phosphate aldolase	<i>fucA</i>	FCL1P <→ LACAL + T3P2	1
Lactaldehyde reductase	<i>fucO</i>	LACAL + NADH <→ 12PPD + NAD	1
Aldehyde dehydrogenase A	<i>aldA</i>	LACAL + NAD <→ LLAC + NADH	1
Aldehyde dehydrogenase B	<i>aldB</i>	LACAL + NAD <→ LLAC + NADH	1
Aldehyde dehydrogenase	<i>adhC</i>	LACAL + NAD <→ LLAC + NADH	1
Aldehyde dehydrogenase	<i>adhC</i>	GLAL + NADH <→ GL + NAD	1
Aldehyde dehydrogenase	<i>adhE</i>	LACAL + NAD → LLAC + NADH	1
Aldehyde dehydrogenase	<i>aldH</i>	LACAL + NAD <→ LLAC + NADH	1
Aldehyde dehydrogenase	<i>aldH</i>	ACAL + NAD → AC + NADH	1
Gluconokinase I	<i>gntV</i>	GLCN + ATP → D6PGC + ADP	1
Gluconokinase II	<i>gntK</i>	GLCN + ATP → D6PGC + ADP	1
L-Rhamnose isomerase	<i>rhaA</i>	RMN <→ RML	1
Rhamnulokinase	<i>rhaB</i>	RML + ATP → RML1P + ADP	1

Enzyme	Gene	Reaction	E. coli genome
Rhamnulose-1-phosphate aldolase	<i>rhaD</i>	RML1P <-> LACAL + T3P2	1
L-Arabinose isomerase	<i>araA</i>	ARAB <-> RBL	1
Arabinose-5-phosphate isomerase		RLSP <-> A5P	0
L-Ribulokinase	<i>araB</i>	RBL + ATP -> RLSP + ADP	1
L-Ribulose-phosphate 4-epimerase	<i>araD</i>	RLSP <-> X5P	1
Xylose isomerase	<i>xylA</i>	XYL <-> XUL	1
Xylulokinase	<i>xylB</i>	XUL + ATP -> X5P + ADP	1
Ribokinase	<i>rbsK</i>	RIB + ATP -> R5P + ADP	1
Mannitol-1-phosphate 5-dehydrogenase	<i>mitD</i>	MNT6P + NAD <-> F6P + NADH	1
Glucitol-6-phosphate dehydrogenase	<i>srhD</i>	GLT6P + NAD <-> F6P + NADH	1
Galactitol-1-phosphate dehydrogenase	<i>galD</i>	GLTL1P + NAD <-> TAG6P + NADH	1
Phosphofructokinase B	<i>pfkB</i>	TAG6P + ATP -> TAG16P + ADP	1
1-Phosphofructokinase	<i>fruK</i>	TAG6P + ATP -> TAG16P + ADP	1
Tagatose-6-phosphate kinase	<i>agaZ</i>	TAG6P + ATP -> TAG16P + ADP	1
Tagatose-bisphosphate aldolase 2	<i>gatY</i>	TAG16P <-> T3P2 + T3P1	1
Tagatose-bisphosphate aldolase 1	<i>agaY</i>	TAG16P <-> T3P2 + T3P1	1
Glycerol kinase	<i>glpK</i>	GL + ATP -> GL3P + ADP	1
Glycerol-3-phosphate-dehydrogenase-[NAD(P)+]	<i>gpsA</i>	GL3P + NADP <-> T3P2 + NADPH	1
Phosphopentomutase	<i>deoB</i>	DR1P <-> DR5P	1
Phosphopentomutase	<i>deoB</i>	R1P <-> R5P	1
Deoxyribose-phosphate aldolase	<i>deoC</i>	DR5P -> ACAL + T3P1	1

Enzyme	Gene	Reaction	E. coli genome
Aspartate transaminase	<i>aspC</i>	OA + GLU <-> ASP + AKG	1
Asparagine synthetase (Glutamate dependent)	<i>asnB</i>	ASP + ATP + GLN -> GLU + ASN + AMP + PPi	1
Aspartate-ammonia ligase	<i>asnA</i>	ASP + ATP + NH3 -> ASN + AMP + PPi	1
Glutamate dehydrogenase	<i>gdhA</i>	AKG + NH3 + NADPH <-> GLU + NAOP	1
Glutamate-ammonia ligase	<i>glnA</i>	GLU + NH3 + ATP -> GLN + ADP + Pi	1
Glutamate synthase	<i>gltBD</i>	AKG + GLN + NADPH -> NADP + 2 GLU	2
Alanine transaminase	<i>alaB</i>	PYR + GLU <-> AKG + ALA	0
Valine-pyruvate aminotransferase	<i>avtA</i>	OIVAL + ALA -> PYR + VAL	1
Alanine racemase, biosynthetic	<i>alr</i>	ALA <-> DALA	1
Alanine racemase, catabolic	<i>dadX</i>	ALA -> DALA	1
N-Acetylglutamate synthase	<i>argA</i>	GLU + ACCOA -> COA + NAGLU	1
N-Acetylglutamate kinase	<i>argB</i>	NAGLU + ATP -> AOP + NAGLUYP	1
N-Acetylglutamate phosphate reductase	<i>argC</i>	NAGLUYP + NADPH <-> NADP + Pi + NAGLUSAL	1
Acetylornithine transaminase	<i>argD</i>	NAGLUSAL + GLU <-> AKG + NAARON	1
Acetylornithine deacetylase	<i>argE</i>	NAARON -> AC + ORN	1
Carbamoyl phosphate synthetase	<i>carAB</i>	GLN + 2 ATP + CO2 -> GLU + CAP + 2 AOP + Pi	2
Ornithine carbamoyl transferase 1	<i>argF</i>	ORN + CAP <-> CITR + Pi	2
Ornithine carbamoyl transferase 2	<i>argI</i>	ORN + CAP <-> CITR + Pi	1
Ornithine transaminase	<i>ygjGH</i>	ORN + AKG -> GLUGSAL + GLU	2
Argininosuccinate synthase	<i>argG</i>	CITR + ASP + ATP -> AMP + PPi + ARGSUCC	1
Argininosuccinate lyase	<i>argH</i>	ARGSUCC <-> FUM + ARG	1

Enzyme	Gene	Reaction	E. coli genome
Arginine decarboxylase, biosynthetic	<i>speA</i>	ARG → CO ₂ + AGM	1
Arginine decarboxylase, degradative	<i>adi</i>	ARG → CD ₂ + AGM	1
Agmatinase	<i>speB</i>	AGM → UREA + PTRC	1
Ornithine decarboxylase, biosynthetic	<i>speC</i>	DRN → PTRC + CO ₂	1
Ornithine decarboxylase, degradative	<i>speF</i>	ORN → PTRC + CO ₂	1
Adenosylmethionine decarboxylase	<i>speD</i>	SAM < → DSAM + CD ₂	1
Spermidine synthase	<i>speE</i>	PTRC + DSAM → SPMD + SMTA	1
Methylthioadenosine nucleosidase		SMTA → AO + 5MTR	0
5-Methylthioribose kinase		5MTR + ATP → 5MTRP + ADP	0
5-Methylthioribose-1-phosphate isomerase		5MTRP < → 5MTR1P	0
E-1 (Endase-phosphatase)		5MTR1P → DKMPP	0
E-3 (Unknown)		DKMPP → FOR + KMB	0
Transamination (Unknown)		KMB + GLN → GLU + MET	0
γ-Glutamyl kinase	<i>proB</i>	GLU + ATP → ADP + GLUP	1
Glutamate-5-semialdehyde dehydrogenase	<i>proA</i>	GLUP + NADPH → NADP + PI + GLUGSAL	1
N-Acetylmurithine deacetylase	<i>argE</i>	NAGLUSAL → GLUGSAL + AC	1
Pyrroline-5-carboxylate reductase	<i>proC</i>	GLUGSAL + NADPH → PRO + NADP	1
Threonine dehydratase, biosynthetic	<i>thrA</i>	THR → NH ₃ + OBUT	1
Threonine dehydratase, catabolic	<i>tdcB</i>	THR → NH ₃ + OBUT	1
Acetohydroxybutanoate synthase I	<i>thrBN</i>	OBUT + PYR → ABUT + CO ₂	2
Acetohydroxybutanoate synthase II	<i>thrG12M</i>	OBUT + PYR → ABUT + CO ₂	3

Enzyme	Gene	Reaction	E. coli genome
Aceto-hydroxybutanoate synthase III	<i>ihvH</i>	OBUT + PYR → ABUT + CO ₂	2
Aceto-hydroxy Acid isomeroreductase	<i>ihvC</i>	ABUT + NADPH → NADP + OHMVA	1
Dihydroxy acid dehydratase	<i>ihvD</i>	OHMVA → OHVAL	1
Branched chain amino acid aminotransferase	<i>ihvE</i>	OHVAL + GLU <→ AKG + ILE	1
Acetolactate synthase I	<i>ihvBN</i>	2 PYR → CO ₂ + ACLAC	2
Acetolactate synthase II	<i>ihvG12M</i>	2 PYR → CO ₂ + ACLAC	3
Acetolactate synthase III	<i>ihvH</i>	2 PYR → CO ₂ + ACLAC	2
Aceto-hydroxy acid isomeroreductase	<i>ihvC</i>	ACLAC + NADPH → NADP + DHVAL	1
Dihydroxy acid dehydratase	<i>ihvD</i>	DHVAL → DIVAL	1
Branched chain amino acid aminotransferase	<i>ihvE</i>	OIVAL + GLU → AKG + VAL	1
Valine-pyruvate aminotransferase	<i>avrA</i>	OIVAL + ALA → PYR + VAL	1
Isopropylmalate synthase	<i>leuA</i>	ACCOA + DIVAL → CDA + CBHCAP	1
Isopropylmalate isomerase	<i>leuCD</i>	CBHCAP <→ IPPMAL	2
3-Isopropylmalate dehydrogenase	<i>leuB</i>	IPPMAL + NAD → NADH + OICAP + CO ₂	1
Branched chain amino acid aminotransferase	<i>ihvE</i>	OICAP + GLU → AKG + LEU	1
Aromatic amino acid transaminase	<i>tyrB</i>	OICAP + GLU → AKG + LEU	1
2-Dehydro-3-deoxyphosphoheptonate aldolase F	<i>araF</i>	E4P + PEP → PI + 3DDAH7P	1
2-Dehydro-3-deoxyphosphoheptonate aldolase G	<i>araG</i>	E4P + PEP → PI + 3DDAH7P	1
2-Dehydro-3-deoxyphosphoheptonate aldolase H	<i>araH</i>	E4P + PEP → PI + 3DDAH7P	1
3-Dehydroquininate synthase	<i>araB</i>	3DDAH7P → DQT + PI	1
3-Dehydroquininate dehydratase	<i>araD</i>	DQT <→ DHSK	1

Enzyme	Gene	Reaction	E. coli genome
Shikimate dehydrogenase	<i>araE</i>	DHSK + NADPH <.> SME + NADP	1
Shikimate kinase I	<i>araK</i>	SME + ATP .> ADP + SME5P	1
Shikimate kinase II	<i>araL</i>	SME + ATP .> ADP + SME5P	1
3-Phosphoshikimate-1-carboxyvinyltransferase	<i>araA</i>	SME5P + PEP <.> 3PSME + PI	1
Chorismate synthase	<i>araC</i>	3PSME .> PI + CHOR	1
Chorismate mutase 1	<i>pheA</i>	CHOR .> PHEN	1
Prephenate dehydratase	<i>pheA</i>	PHEN .> CO2 + PHPYR	1
Aromatic amino acid transaminase	<i>tyrB</i>	PHPYR + GLU <.> AKG + PHE	1
Chorismate mutase 2	<i>tyrA</i>	CHOR .> PHEN	1
Prephenate dehydrogenase	<i>tyrA</i>	PHEN + NAD .> HPHPYR + CO2 + NADH	1
Aromatic amino acid transaminase	<i>tyrB</i>	HPHPYR + GLU <.> AKG + TYR	1
Aspartate transaminase	<i>aspC</i>	HPHPYR + GLU <.> AKG + TYR	1
Anthraniolate synthase	<i>trpDE</i>	CHOR + GLN .> GLU + PYR + AN	2
Anthraniolate synthase component II	<i>trpD</i>	AN + PRPP .> PPI + NPRAN	1
Phosphoribosyl anthranilate isomerase	<i>trpC</i>	NPRAN .> CPAD5P	1
Indoleglycerol phosphate synthase	<i>trpC</i>	CPAD5P .> CO2 + IGP	1
Tryptophan synthase	<i>trpAB</i>	IGP + SER .> T3P1 + TRP	2
Phosphoribosyl pyrophosphate synthase	<i>prsA</i>	R5P + ATP <.> PRPP + AMP	1
ATP phosphoribosyltransferase	<i>hisG</i>	PRPP + ATP .> PPI + PRBATP	1
Phosphoribosyl-ATP pyrophosphatase	<i>hisE</i>	PRBATP .> PPI + PRBAMP	1
Phosphoribosyl-AMP cyclohydrolase	<i>hisE</i>	PRBAMP .> PRFP	1

Enzyme	Gene	Reaction	E. coli genome
Phosphoribosylformimino-5-amino-1-phosphoribosyl-4-imidazole carboxamide isomerase	<i>hisA</i>	PRFP → PRLP	1
Imidazoleglycerol phosphate synthase	<i>hisFH</i>	PRLP + GLN → GLU + AICAR + DIMGP	2
Imidazoleglycerol phosphate dehydratase	<i>hisB</i>	DIMGP → IMACP	1
L-Histidinol phosphate aminotransferase	<i>hisC</i>	IMACP + GLU → AKG + HISOLP	1
Histidinol phosphatase	<i>hisB</i>	HISOLP → PI + HISOL	1
Histidinol dehydrogenase	<i>hisD</i>	HISOL + 3 NAD → HIS + 3 NADH	1
3-Phosphoglycerate dehydrogenase	<i>serA</i>	3PG + NAD → NADH + PHP	1
Phosphoserine transaminase	<i>serC</i>	PHP + GLU → AKG + 3PSER	1
Phosphoserine phosphatase	<i>serB</i>	3PSER → PI + SER	1
Glycine hydroxymethyltransferase	<i>glyA</i>	THF + SER → GLY + METHF	1
Threonine dehydrogenase	<i>tdh</i>	THR + COA → GLY + ACCOA	1
Amino ketobutyrate CoA ligase	<i>kbl</i>	THR + COA → GLY + ACCOA	1
Sulfate adenylyltransferase	<i>cysDN</i>	SLF + ATP + GTP → PPI + APS + GDP + PI	2
Adenylylsulfate kinase	<i>cysC</i>	APS + ATP → ADP + PAPS	1
3'-Phospho-adenylylsulfate reductase	<i>cysH</i>	PAPS + RTHIO → OTHIO + H ₂ S ₀₃ + PAP	1
Sulfite reductase	<i>cysJ</i>	H ₂ S ₀₃ + 3 NADPH <-> H ₂ S + 3 NADP	2
Serine transacetylase	<i>cysE</i>	SER + ACCOA <-> COA + ASER	1
O-Acetylserine (thiol)-lyase A	<i>cysK</i>	ASER + H ₂ S → AC + CYS	1
O-Acetylserine (thiol)-lyase B	<i>cysM</i>	ASER + H ₂ S → AC + CYS	1
3' - 5' Bispophosphate nucleotidase		PAP → AMP + PI	0

Enzyme	Gene	Reaction	E. coli genome
Aspartate kinase I	<i>thrA</i>	ASP + ATP \rightarrow ADP + BASP	1
Aspartate kinase II	<i>metL</i>	ASP + ATP \rightarrow ADP + BASP	1
Aspartate kinase III	<i>lysC</i>	ASP + ATP \rightarrow ADP + BASP	1
Aspartate semialdehyde dehydrogenase	<i>asd</i>	BASP + NADPH \rightarrow NADP + PI + ASPSA	1
Homoserine dehydrogenase I	<i>thrA</i>	ASPSA + NADPH \rightarrow NADP + HSER	1
Homoserine dehydrogenase II	<i>metL</i>	ASPSA + NADPH \rightarrow NADP + HSER	1
Homoserine kinase	<i>thrB</i>	HSER + ATP \rightarrow ADP + PHSER	1
Threonine synthase	<i>thrC</i>	PHSER \rightarrow PI + THR	1
Dihydrodipicolinate synthase	<i>dapA</i>	ASPSA + PYR \rightarrow D23PIC	1
Dihydrodipicolinate reductase	<i>dapB</i>	D23PIC + NADPH \rightarrow NADP + PIP26DX	1
Tetrahydrodipicolinate succinylase	<i>dapD</i>	PIP26DX + SUCCOA \rightarrow COA + NS2A60	1
Succinyl diaminopimelate aminotransferase	<i>dapC</i>	NS2A60 + GLU \rightarrow AKG + NS26DP	0
Succinyl diaminopimelate desuccinylase	<i>dapE</i>	NS26DP \rightarrow SUCC + D26PIM	1
Diaminopimelate epimerase	<i>dapF</i>	D26PIM \rightarrow MDAP	1
Diaminopimelate decarboxylase	<i>lysA</i>	MDAP \rightarrow CO2 + LYS	1
Lysine decarboxylase 1	<i>cadA</i>	LYS \rightarrow CO2 + CADV	1
Lysine decarboxylase 2	<i>ldcC</i>	LYS \rightarrow CO2 + CADV	1
Homoserine transsuccinylase	<i>metA</i>	HSER + SUCCOA \rightarrow COA + OSLHSER	1
O-succinylhomoserine lyase	<i>metB</i>	OSLHSER + CYS \rightarrow SUCC + LLCT	1
Cystathionine- β -lyase	<i>metC</i>	LLCT \rightarrow HCYS + PYR + NH3	1
Adenosyl homocysteinease (Unknown)	<i>Unknown</i>	HCYS + ADN \rightarrow SAH	0

Enzyme	Gene	Reaction	E. coli genome
Cobalamin-dependent methionine synthase	<i>metH</i>	HCYS + MTHF → MET + THF	1
Cobalamin-independent methionine synthase	<i>metE</i>	HCYS + MTHF → MET + THF	1
S-Adenosylmethionine synthetase	<i>metK</i>	MET + ATP → PPI + PI + SAM	1
D-Amino acid dehydrogenase	<i>dadA</i>	DALA + FAD → FADH + PYR + NH ₃	1
Putrescine transaminase	<i>par</i>	PTRC + AKG → GABAL + GLU	0
Amino oxidase	<i>tyrA</i>	PTRC → GABAL + NH ₃	1
Aminobutyraldehyde dehydrogenase	<i>prf</i>	GABAL + NAD → GABA + NADH	0
Aldehyde dehydrogenase	<i>aldH</i>	GABAL + NAD → GABA + NADH	1
Aminobutyrate aminotransaminase 1	<i>gabT</i>	GABA + AKG → SUCCSAL + GLU	1
Aminobutyrate aminotransaminase 2	<i>goaG</i>	GABA + AKG → SUCCSAL + GLU	1
Succinate semialdehyde dehydrogenase -NAD	<i>sad</i>	SUCCSAL + NAD → SUCC + NADH	0
Succinate semialdehyde dehydrogenase -NADP	<i>gabD</i>	SUCCSAL + NADP → SUCC + NADPH	1
Asparaginase I	<i>ansA</i>	ASN → ASP + NH ₃	1
Asparaginase II	<i>ansB</i>	ASN → ASP + NH ₃	1
Aspartate ammonia-lyase	<i>aspA</i>	ASP → FUM + NH ₃	1
Tryptophanase	<i>tnaA</i>	CYS → PYR + NH ₃ + H ₂ S	1
L-Cysteine desulhydrase		CYS → PYR + NH ₃ + H ₂ S	0
Glutamate decarboxylase A	<i>gadA</i>	GLU → GABA + CO ₂	1
Glutamate decarboxylase B	<i>gadB</i>	GLU → GABA + CO ₂	1
Glutaminase A		GLN → GLU + NH ₃	0
Glutaminase B		GLN → GLU + NH ₃	0

Enzyme	Gene	Reaction	E. coli genome
Proline dehydrogenase	<i>putA</i>	PRO + FAD -> FADH + GLUGSAL	1
Pyrroline-5-carboxylate dehydrogenase	<i>putA</i>	GLUGSAL + NAD -> NADH + GLU	1
Serine deaminase 1	<i>sdaA</i>	SER -> PYR + NH3	1
Serine deaminase 2	<i>sdaB</i>	SER -> PYR + NH3	1
Tryptophanase	<i>tnaA</i>	SER -> PYR + NH3	1
D-Serine deaminase	<i>dsdA</i>	DSER -> PYR + NH3	1
Threonine dehydrogenase	<i>tdh</i>	THR + NAO -> 2A3O + NADH	1
Amino ketobutyrate ligase	<i>kbl</i>	2A3O + COA -> ACCOA + GLY	1
Threonine dehydratase catabolic	<i>tdcB</i>	THR -> OBUT + NH3	1
Threonine deaminase 1	<i>sdaA</i>	THR -> OBUT + NH3	1
Threonine deaminase 2	<i>sdaB</i>	THR -> OBUT + NH3	1
Tryptophanase	<i>tnaA</i>	TRP -> INDOL + PYR + NH3	1
Amidophosphoribosyl transferase	<i>purF</i>	PRPP + GLN -> PPI + GLU + PRAM	1
Phosphoribosylamine-glycine ligase	<i>purD</i>	PRAM + ATP + GLY -> ADP + PI + GAR	1
Phosphoribosylglycinamide formyltransferase	<i>purN</i>	GAR + FTHF -> THF + FGAR	1
GAR transferase T	<i>purT</i>	GAR + FOR + ATP -> ADP + PI + FGAR	1
Phosphoribosylformylglycinamide synthetase	<i>purL</i>	FGAR + ATP + GLN -> GLU + ADP + PI + FGAM	1
Phosphoribosylformylglycinamide cyclo-ligase	<i>purM</i>	FGAM + ATP -> ADP + PI + AIR	1
Phosphoribosylaminoimidazole carboxylase 1	<i>purK</i>	AIR + CO2 + ATP -> ADP -> NCAIR + ADP + PI	1
Phosphoribosylaminoimidazole carboxylase 2	<i>purE</i>	NCAIR -> CAIR	1
Phosphoribosylaminoimidazole-succinocarboxamide synthetase	<i>purC</i>	CAIR + ATP + ASP -> ADP + PI + SAICAR	1

Enzyme	Gene	Reaction	E. coli genome
5'-Phosphoribosyl-4-(N-succinocarboxamide)-5-aminimidazole lyase	<i>purB</i>	SAICAR \rightarrow FUM + AICAR	1
AICAR transformylase	<i>purH</i>	AICAR + FTHF \rightarrow THF + PRFICA	1
IMP cyclohydrolase	<i>purH</i>	PRFICA \rightarrow IMP	1
Adenylosuccinate synthetase	<i>purA</i>	IMP + GTP + ASP \rightarrow GDP + PI + ASUC	1
Adenylosuccinate lyase	<i>purB</i>	ASUC \rightarrow FUM + AMP	1
IMP dehydrogenase	<i>guaB</i>	IMP + NAD \rightarrow NADH + XMP	1
GMP synthase	<i>guaA</i>	XMP + ATP + GLN \rightarrow GLU + AMP + PPI + GMP	1
GMP reductase	<i>guaC</i>	GMP + NADPH \rightarrow NADP + IMP + NH ₃	1
Aspartate-carbamoyltransferase	<i>pyrB1</i>	CAP + ASP \rightarrow CAASP + PI	2
Dihydroorotase	<i>pyrC</i>	CAASP \rightarrow DOROA	1
Dihydroorotate dehydrogenase	<i>pyrD</i>	DOROA + Q \rightarrow QH ₂ + OROA	1
Orotate phosphoribosyl transferase	<i>pyrE</i>	OROA + PRPP \rightarrow PPI + OMP	1
OMP decarboxylase	<i>pyrF</i>	OMP \rightarrow CO ₂ + UMP	1
CTP synthetase	<i>pyrG</i>	UTP + GLN + ATP \rightarrow GLU + CTP + ADP + PI	1
Adenylyate kinase	<i>adk</i>	ATP + AMP \rightarrow 2 ADP	1
Adenylyate kinase	<i>adk</i>	GTP + AMP \rightarrow ADP + GDP	1
Adenylyate kinase	<i>adk</i>	ITP + AMP \rightarrow ADP + IDP	1
Adenylyate kinase	<i>adk</i>	DAMP + ATP \rightarrow ADP + DADP	1
Guanylyate kinase	<i>gmK</i>	GMP + ATP \rightarrow GDP + ADP	1
Deoxyguanylyate kinase	<i>gmK</i>	DGMP + ATP \rightarrow DGDP + ADP	1

Enzyme	Gene	Reaction	E. coli genome
Nucleoside-diphosphate kinase	<i>ndk</i>	GDP + ATP \rightarrow GTP + ADP	1
Nucleoside-diphosphate kinase	<i>ndk</i>	UDP + ATP \rightarrow UTP + ADP	1
Nucleoside-diphosphate kinase	<i>ndk</i>	CDP + ATP \rightarrow CTP + ADP	1
Nucleoside-diphosphate kinase	<i>ndk</i>	DGDP + ATP \rightarrow DGTP + ADP	1
Nucleoside-diphosphate kinase	<i>ndk</i>	DUDP + ATP \rightarrow DUTP + ADP	1
Nucleoside-diphosphate kinase	<i>ndk</i>	DCDP + ATP \rightarrow DCTP + ADP	1
Nucleoside-diphosphate kinase	<i>ndk</i>	DADP + ATP \rightarrow DATP + ADP	1
Nucleoside-diphosphate kinase	<i>ndk</i>	DTDP + ATP \rightarrow DTTT + ADP	1
AMP Nucleosidase	<i>amn</i>	AMP \rightarrow AD + R5P	1
Adenosine deaminase	<i>add</i>	ADN \rightarrow INS + NH ₃	1
Deoxyadenosine deaminase	<i>add</i>	DA \rightarrow DIN + NH ₃	1
Adenine deaminase	<i>yicP</i>	AD \rightarrow NH ₃ + HYXN	1
Inosine kinase	<i>gsk</i>	INS + ATP \rightarrow IMP + ADP	1
Guanosine kinase	<i>gsk</i>	GSN + ATP \rightarrow GMP + ADP	1
Adenosine kinase	<i>adk</i>	ADN + ATP \rightarrow AMP + ADP	1
Adenine phosphoryltransferase	<i>apt</i>	AD + PRPP \rightarrow PPI + AMP	1
Xanthine-guanine phosphoribosyltransferase	<i>gpt</i>	XAN + PRPP \rightarrow XMP + PPI	1
Xanthine-guanine phosphoribosyltransferase	<i>gpt</i>	HYXN + PRPP \rightarrow PPI + IMP	1
Hypoxanthine phosphoribosyltransferase	<i>hpt</i>	HYXN + PRPP \rightarrow PPI + IMP	1
Xanthine-guanine phosphoribosyltransferase	<i>gpt</i>	GN + PRPP \rightarrow PPI + GMP	1
Hypoxanthine phosphoribosyltransferase	<i>hpt</i>	GN + PRPP \rightarrow PPI + GMP	1

Enzyme	Gene	Reaction	E. coli genome
Xanthosine phosphorylase	<i>xapA</i>	DIN + PI \rightarrow HYXN + DR1P	1
Purine nucleotide phosphorylase	<i>deoD</i>	DIN + PI \rightarrow HYXN + DR1P	1
Xanthosine phosphorylase	<i>xapA</i>	DA + PI \rightarrow AD + DR1P	1
Purine nucleotide phosphorylase	<i>deoD</i>	DA + PI \rightarrow AD + DR1P	1
Xanthosine phosphorylase	<i>xapA</i>	DG + PI \rightarrow GN + DR1P	1
Purine nucleotide phosphorylase	<i>deoD</i>	DG + PI \rightarrow GN + DR1P	1
Xanthosine phosphorylase	<i>xapA</i>	HYXN + R1P \rightarrow INS + PI	1
Purine nucleotide phosphorylase	<i>deoD</i>	HYXN + R1P \rightarrow INS + PI	1
Xanthosine phosphorylase	<i>xapA</i>	AD + R1P \rightarrow PI + ADN	1
Purine nucleotide phosphorylase	<i>deoD</i>	AD + R1P \rightarrow PI + ADN	1
Xanthosine phosphorylase	<i>xapA</i>	GN + R1P \rightarrow PI + GSN	1
Purine nucleotide phosphorylase	<i>deoD</i>	GN + R1P \rightarrow PI + GSN	1
Xanthosine phosphorylase	<i>xapA</i>	XAN + R1P \rightarrow PI + XTSN	1
Purine nucleotide phosphorylase	<i>deoD</i>	XAN + R1P \rightarrow PI + XTSN	1
Uridine phosphorylase	<i>udp</i>	URI + PI \rightarrow URA + R1P	1
Thymidine (deoxyuridine) phosphorylase	<i>deoA</i>	DU + PI \rightarrow URA + DR1P	1
Purine nucleotide phosphorylase	<i>deoD</i>	DU + PI \rightarrow URA + DR1P	1
Thymidine (deoxyuridine) phosphorylase	<i>deoA</i>	OT + PI \rightarrow THY + DR1P	1
Cytidylate kinase	<i>cmkA</i>	DCMP + ATP \rightarrow ADP + DCDP	1
Cytidylate kinase	<i>cmkA</i>	CMP + ATP \rightarrow ADP + CDP	1
Cytidylate kinase	<i>cmkB</i>	DCMP + ATP \rightarrow ADP + DCDP	1

Enzyme	Gene	Reaction	E. coli genome
Cytidylate kinase	<i>cmkB</i>	CMP + ATP \rightarrow ADP + CDP	1
Cytidylate kinase	<i>cmkA</i>	UMP + ATP \rightarrow ADP + UDP	1
Cytidylate kinase	<i>cmkB</i>	UMP + ATP \rightarrow ADP + UDP	1
dTMP kinase	<i>tnk</i>	DTMP + ATP \rightarrow ADP + dTDP	1
Uridylate kinase	<i>pyrH</i>	UMP + ATP \rightarrow UDP + ADP	1
Uridylate kinase	<i>pyrH</i>	DUMP + ATP \rightarrow DUDP + ADP	1
Thymidine (deoxyuridine) kinase	<i>tdk</i>	DU + ATP \rightarrow DUMP + ADP	1
Uracil phosphoribosyltransferase	<i>upp</i>	URA + PRPP \rightarrow UMP + PPi	1
Cytosine deaminase	<i>codA</i>	CYTS \rightarrow URA + NH ₃	1
Uridine kinase	<i>udk</i>	URI + GTP \rightarrow GDP + UMP	1
Cytidine kinase	<i>udk</i>	CYTD + GTP \rightarrow GDP + CMP	1
CMP glycosylase		CMP \rightarrow CYTS + R5P	0
Cytidine deaminase	<i>cdd</i>	CYTD \rightarrow URI + NH ₃	1
Thymidine (deoxyuridine) kinase	<i>tdk</i>	DT + ATP \rightarrow ADP + DTMP	1
dCTP deaminase	<i>dcd</i>	dCTP \rightarrow dUTP + NH ₃	1
Cytidine deaminase	<i>cdd</i>	DC \rightarrow NH ₃ + DU	1
5'-Nucleotidase	<i>ushA</i>	DUMP \rightarrow DU + PI	1
5'-Nucleotidase	<i>ushA</i>	DTMP \rightarrow DT + PI	1
5'-Nucleotidase	<i>ushA</i>	DAMP \rightarrow DA + PI	1
5'-Nucleotidase	<i>ushA</i>	DGMP \rightarrow DG + PI	1
5'-Nucleotidase	<i>ushA</i>	DCMP \rightarrow DC + PI	1

Enzyme	Gene	Reaction	E. coli genome
5'-Nucleotidase	<i>ushA</i>	CMP → CYTD + PI	1
5'-Nucleotidase	<i>ushA</i>	AMP → PI + AON	1
5'-Nucleotidase	<i>ushA</i>	GMP → PI + GSN	1
5'-Nucleotidase	<i>ushA</i>	IMP → PI + INS	1
5'-Nucleotidase	<i>ushA</i>	XMP → PI + XTSN	1
5'-Nucleotidase	<i>ushA</i>	UMP → PI + URI	1
Ribonucleoside-diphosphate reductase	<i>nrdAB</i>	AOP + RTHIO → OAOP + OTHIO	2
Ribonucleoside-diphosphate reductase	<i>nrdAB</i>	GOP + RTHIO → DGOP + OTHIO	2
Ribonucleoside-triphosphate reductase	<i>nrdD</i>	ATP + RTHIO → DATP + OTHIO	1
Ribonucleoside-triphosphate reductase	<i>nrdD</i>	GTP + RTHIO → DGTP + OTHIO	1
Ribonucleoside-diphosphate reductase	<i>nrdAB</i>	COP + RTHIO → DCOP + OTHIO	2
Ribonucleoside-diphosphate reductase II	<i>nrdEF</i>	CDP + RTHIO → DCDP + OTHIO	2
Ribonucleoside-diphosphate reductase	<i>nrdAB</i>	UOP + RTHIO → OUOP + OTHIO	2
Ribonucleoside-triphosphate reductase	<i>nrdD</i>	CTP + RTHIO → OCTP + OTHIO	1
Ribonucleoside-triphosphate reductase	<i>nrdD</i>	UTP + RTHIO → OTHIO + DUTP	1
dUTP pyrophosphatase	<i>dut</i>	DUTP → PPI + DUMP	1
Thymidilate synthetase	<i>thyA</i>	DUMP + METHF → DHF + DTMP	1
Nucleoside triphosphatase	<i>mutT</i>	GTP → GSN + 3 PI	1
Nucleoside triphosphatase	<i>mutT</i>	DGTP → DG + 3 PI	1
Deoxyguanosinetriphosphate triphosphohydrolase	<i>dgt</i>	DGTP → DG + 3 PI	1
Deoxyguanosinetriphosphate triphosphohydrolase	<i>dgt</i>	GTP → GSN + 3 PI	1

Enzyme	Gene	Reaction	E. coli genome
Glycine cleavage system (Multi-component system)	<i>gcvHTP, lpdA</i>	GLY + THF + NAD → METHF + NADH + CO ₂ + NH ₃	4
Formyl tetrahydrofolate deformylase	<i>purU</i>	FTHF → FDR + THF	1
Methylene tetrahydrofolate reductase	<i>metF</i>	METHF + NADH → NAD + MTHF	1
Methylene THF dehydrogenase	<i>folD</i>	METHF + NADP <→ METHF + NADPH	1
Methenyl tetrahydrofolate cyclehydrilase	<i>folD</i>	METHF <→ FTHF	1
Acetyl-CoA carboxyltransferase	<i>accABD</i>	ACCoA + ATP + CO ₂ <→ MALCoA + ADP + PI	3
Malonyl-CoA-ACP transacylase	<i>fabD</i>	MALCoA + ACP <→ MALACP + CoA	1
Malonyl-ACP decarboxylase	<i>fabB</i>	MALACP → ACACP + CO ₂	1
Acetyl-CoA-ACP transacylase	<i>fabH</i>	ACACP + CoA <→ ACCoA + ACP	1
Acyltransferase	<i>pls</i>	GL3P + 0.035 C140ACP + 0.102 C141ACP + 0.717 C160ACP + 0.142 C161ACP + 1.004 C181ACP → 2 ACP + PA	0
CDP-Diacylglycerol synthetase	<i>cdsA</i>	PA + CTP <→ CDPDG + PPI	1
CDP-Diacylglycerol pyrophosphatase	<i>cdh</i>	CDPDG → CMP + PA	1
Phosphatidylserine synthase	<i>pssA</i>	CDPDG + SER <→ CMP + PS	1
Phosphatidylserine decarboxylase	<i>psd</i>	PS → PE + CO ₂	1
Phosphatidylglycerol phosphate synthase	<i>pgsA</i>	CDPDG + GL3P <→ CMP + PGP	1
Phosphatidylglycerol phosphate phosphatase A	<i>pgpA</i>	PGP → PI + PG	0
Phosphatidylglycerol phosphate phosphatase B	<i>pgpB</i>	PGP → PI + PG	1
Cardiolipin synthase	<i>cls</i>	2 PG <→ CL + GL	1
Acetyl-CoA C-acetyltransferase	<i>atoB</i>	2 ACCoA <→ CoA + AACCoA	1
Isoprenyl-pyrophosphate synthesis pathway		T3P1 + PYR + 2 NADPH + ATP → IPPP + ADP + 2 NADP + CO ₂	0

Enzyme	Gene	Reaction	E. coli genome
Isoprenyl pyrophosphate isomerase		IPPP → DMPP	0
Farnesyl pyrophosphate synthetase	<i>ispA</i>	DMPP + IPPP → GPP + PPI	1
Geranyltransferase	<i>ispA</i>	GPP + IPPP → FPP + PPI	1
Octaprenyl pyrophosphate synthase (5 reactions)	<i>ispB</i>	5 IPPP + FPP → OPP + 5 PPI	1
Undecaprenyl pyrophosphate synthase (8 reactions)		8 IPPP + FPP → UDPP + 8 PPI	0
Chorismate pyruvate-lyase	<i>ubiC</i>	CHOR → 4HBZ + PYR	1
Hydroxybenzoate octaprenyltransferase	<i>ubiA</i>	4HBZ + OPP → O4HBZ + PPI	1
Octaprenyl-hydroxybenzoate decarboxylase	<i>ubiD, ubiX</i>	O4HBZ → CO ₂ + 20PPP	1
2-Octaprenylphenol hydroxylase	<i>ubiB</i>	20PPP + O ₂ → 206H	1
Methylation reaction		206H + SAM → 20PMP + SAH	0
2-Octaprenyl-6-methoxyphenol hydroxylase	<i>ubiH</i>	20PMP + O ₂ → 20PMB	1
2-Octaprenyl-6-methoxy-1,4-benzoquinone methylase	<i>ubiE</i>	20PMB + SAM → 20PMMB + SAH	0
2-Octaprenyl-3-methyl-6-methoxy-1,4-benzoquinone hydroxylase	<i>ubiF</i>	20PMMB + O ₂ → 20MHMB	0
3-Dimethylubiquinone 3-methyltransferase	<i>ubiG</i>	20MHMB + SAM → QH ₂ + SAH	1
Isochorismate synthase 1	<i>menF</i>	CHOR → ICHOR	1
α-Ketoglutarate decarboxylase	<i>menD</i>	AKG + TPP → SSALTPP + CO ₂	1
SHCHC synthase	<i>menD</i>	ICHOR + SSALTPP → PYR + TPP + SHCHC	1
O-Succinylbenzoate-CoA synthase	<i>menC</i>	SHCHC → OSB	1
O-Succinylbenzoic acid-CoA ligase	<i>menE</i>	OSB + ATP + COA → OSBCOA + AMP + PPI	1
Naphthoate synthase	<i>menB</i>	OSBCOA → DHNA + COA	1

Enzyme	Gene	Reaction	E. coli genome
1,4-Dihydroxy-2-naphthoate octaprenyltransferase	<i>menA</i>	DHNA + OPP -> DMK + PPI + CD2	1
S-Adenosylmethionine-2-DMK methyltransferase	<i>menG</i>	DMK + SAM -> MK + SAH	1
Isochorismate synthase 2	<i>entC</i>	CHOR -> ICHOR	1
Isochorismatase	<i>entB</i>	ICHOR <-> 23DHDB + PYR	1
2,3-Dihydro-2,3-dihydroxybenzoate dehydrogenase	<i>entA</i>	23DHDB + NAD <-> 23DHB + NADH	1
ATP-dependent activation of 2,3-dihydroxybenzoate	<i>entE</i>	23DHB + ATP <-> 23DHBA + PPI	1
ATP-dependent serine activating enzyme	<i>entF</i>	SER + ATP <-> SERA + PPI	1
Enterocoein synthetase	<i>entD</i>	3 SERA + 3 23DHBA -> ENTER + 6 AMP	1
GTP cyclohydrolase II	<i>ribA</i>	GTP -> D6RP5P + FOR + PPI	1
Pyrimidine deaminase	<i>ribD</i>	D6RP5P -> A6RP5P + NH3	1
Pyrimidine reductase	<i>ribD</i>	A6RP5P + NADPH -> A6RP5P2 + NADP	1
Pyrimidine phosphatase		A6RP5P2 -> A6RP + PI	0
3,4-Dihydroxy-2-butanone-4-phosphate synthase	<i>ribB</i>	RL5P -> DB4P + FDR	1
6,7-Dimethyl-8-ribityllumazine synthase	<i>ribE</i>	DB4P + A6RP -> D8RL + PI	1
Riboflavin synthase	<i>ribH</i>	2 D8RL -> RIBFLV + A6RP	1
Riboflavin kinase	<i>ribF</i>	RIBFLV + ATP -> FMN + ADP	1
FAD synthetase	<i>ribF</i>	FMN + ATP -> FAD + PPI	1
GTP cyclohydrolase I	<i>folE</i>	GTP -> FOR + AHTD	1
Dihydroneopterin triphosphate pyrophosphorylase	<i>nipA</i>	AHTD -> PPI + DHPP	1
Nucleoside triphosphatase	<i>mutT</i>	AHTD -> DHP + 3 PI	1
Dihydroneopterin monophosphate dephosphorylase		DHPP -> DHP + PI	0

Enzyme	Gene	Reaction	E. coli genome
Dihydroneopterin aldolase	<i>folB</i>	DHP -> AHHMP + GLAL	1
6-Hydroxymethyl-7,8 dihydropterin pyrophosphokinase	<i>folK</i>	AHHMP + ATP -> AMP + AHHMO	1
Aminodeoxychorismate synthase	<i>pabAB</i>	CHOR + GLN -> AOCHOR + GLU	2
Aminodeoxychorismate lyase	<i>pabC</i>	ADCHOR -> PYR + PABA	1
Oihydropteroate synthase	<i>folP</i>	PABA + AHHMD -> PPI + DHPT	1
Dihydrofolate synthetase	<i>folC</i>	DHPT + ATP + GLU -> AOP + PI + DHF	1
Dihydrofolate reductase	<i>folA</i>	DHF + NADPH -> NADP + THF	1
Ketopantoate hydroxymethyl transferase	<i>panB</i>	OIVAL + METTHF -> AKP + THF	1
Ketopantoate reductase	<i>panE</i>	AKP + NADPH -> NADP + PANT	0
Acetohydroxyacid isomeroreductase	<i>ilvC</i>	AKP + NADPH -> NADP + PANT	1
Aspartate decarboxylase	<i>panD</i>	ASP -> CO2 + BALA	1
Pantoate-β-alanine ligase	<i>panC</i>	PANT + BALA + ATP -> AMP + PPI + PNTD	1
Pantothenate kinase	<i>coaA</i>	PNTD + ATP -> ADP + 4PPNTD	1
Phosphopantothenate-cysteine ligase		4PPNTD + CTP + CYS -> CMP + PPI + 4PPNCYS	0
Phosphopantothenate-cysteine decarboxylase		4PPNCYS -> CO2 + 4PPNTE	0
Phospho-pantetheine adenyltransferase		4PPNTE + ATP -> PPI + DPCOA	0
DephosphoCoA kinase		DPCOA + ATP -> ADP + COA	0
ACP Synthase	<i>acpS</i>	COA -> PAP + ACP	1
Aspartate oxidase	<i>nadB</i>	ASP + FAD -> FADH + ISUCC	1
Quinolinate synthase	<i>nadA</i>	ISUCC + T3P2 -> PI + QA	1

Enzyme	Gene	Reaction	E. coli genome
Quinolate phosphoribosyl transferase	<i>nadC</i>	QA + PRPP → NAMN + CO ₂ + PPI	1
NAMN adenylyl transferase	<i>nadD</i>	NAMN + ATP → PPI + NAAD	0
NAMN adenylyl transferase	<i>nadD</i>	NMN + ATP → NAD + PPI	0
Deamido-NAD ammonia ligase	<i>nadE</i>	NAAD + ATP + NH ₃ → NAD + AMP + PPI	1
NAD kinase	<i>nadFG</i>	NAD + ATP → NAOP + ADP	0
NADP phosphatase		NAOP → NAD + Pi	0
DNA ligase	<i>lig</i>	NAD → NMN + AMP	1
NMN amidohydrolase	<i>pncC</i>	NMN → NAMN + NH ₃	0
NMN glycohydrolase (cytoplasmic)		NMN → R5P + Nam	0
NAm amidohydrolase	<i>pncA</i>	NAm → NAC + NH ₃	0
NAPRTase	<i>pncB</i>	NAC + PRPP + ATP → NAMN + PPI + Pi + ADP	1
NAD pyrophosphatase	<i>pnuE</i>	NADxt → NMNxt + AMPxt	0
NMN permease	<i>pnuC</i>	NMNxt → NMN	1
NMN glycohydrolase (membrane bound)		NMNxt → R5P + Nam	0
Nicotinic acid uptake		NACxt → NAC	0
GSA synthetase	<i>hemM</i>	GLU + ATP → GTRNA + AMP + PPI	1
Glutamyl-tRNA synthetase	<i>glx</i>	GLU + ATP → GTRNA + AMP + PPI	1
Glutamyl-tRNA reductase	<i>hemA</i>	GTRNA + NADPH → GSA + NADP	1
Glutamate-1-semialdehyde aminotransferase	<i>hemL</i>	GSA → ALAV	1
Porphobilinogen synthase	<i>hemB</i>	8 ALAV → 4 PBG	1
Hydroxymethylbilane synthase	<i>hemC</i>	4 PBG → HMB + 4 NH ₃	1

Enzyme	Gene	Reaction	E. coli genome
Uroporphyrinogen III synthase	<i>hemD</i>	HMB -> UPRG	1
Uroporphyrin-III C-methyltransferase 1	<i>hemX</i>	SAM + UPRG -> SAH + PC2	1
Uroporphyrin-III C-methyltransferase 2	<i>cysG</i>	SAM + UPRG -> SAH + PC2	1
1,3-Dimethyluroporphyrinogen III dehydrogenase	<i>cysG</i>	PC2 + NAD -> NADH + SHCL	1
Siroheme ferrochelatase	<i>cysG</i>	SHCL -> SHEME	1
Uroporphyrinogen decarboxylase	<i>hemE</i>	UPRG -> 4 CO2 + CPP	1
Coproporphyrinogen oxidase, aerobic	<i>hemF</i>	O2 + CPP -> 2 CO2 + PPHG	2
Protoporphyrinogen oxidase	<i>hemG</i>	O2 + PPHG -> PPIX	2
Ferrochelatase	<i>hemH</i>	PPIX -> PTH	1
Heme O synthase	<i>cyoE</i>	PTH + FPP -> HO + PPI	1
8-Amino-7-oxononanoate synthase	<i>bioF</i>	ALA + CHCOA <-> CO2 + COA + AONA	1
Adenosylmethionine-8-amino-7-oxononanoate aminotransferase	<i>bioA</i>	SAM + AONA <-> SAMOB + DANNA	1
Dethiobiotin synthase	<i>bioD</i>	CO2 + DANNA + ATP <-> DTB + P1 + ADP	1
Biotin synthase	<i>bioB</i>	DTB + CYS <-> BT	1
Glutamate-cysteine ligase	<i>gshA</i>	CYS + GLU + ATP -> GC + P1 + ADP	1
Glutathione synthase	<i>gshB</i>	GLY + GC + ATP -> RGT + P1 + ADP	1
Glutathione reductase	<i>gor</i>	NADPH + OGT <-> NADP + RGT	1
thiC protein	<i>thiC</i>	AIR -> AHM	1
HMP kinase	<i>thiN</i>	AHM + ATP -> AHMP + ADP	0
HMP-phosphate kinase	<i>thiD</i>	AHMP + ATP -> AHMPP + ADP	0

Enzyme	Gene	Reaction	E. coli genome
Hypothetical		T3P1 + PYR -> DTP	0
thiG protein	<i>thiG</i>	DTP + TYR + CYS -> THZ + HBA + C02	1
thiE protein	<i>thiE</i>	DTP + TYR + CYS -> THZ + HBA + C02	1
thiF protein	<i>thiF</i>	DTP + TYR + CYS -> THZ + HBA + C02	1
thiH protein	<i>thiH</i>	DTP + TYR + CYS -> THZ + HBA + C02	1
THZ kinase	<i>thiM</i>	THZ + ATP -> THZP + ADP	0
Thiamin phosphate synthase	<i>thiB</i>	THZP + AHMPP -> THMP + PPI	0
Thiamin kinase	<i>thiK</i>	THMP + ADP -> THIAMIN + ATP	0
Thiamin phosphate kinase	<i>thiL</i>	THMP + ATP -> TPP + ADP	0
Erythrose 4-phosphate dehydrogenase	<i>epd</i>	E4P + NAD -> ER4P + NADH	1
Erythronate-4-phosphate dehydrogenase	<i>pdxB</i>	ER4P + NAD -> OHB + NADH	1
Hypothetical transaminase/phosphoserine transaminase	<i>serC</i>	OHB + GLU -> PHT + AKG	1
Pyridoxal-phosphate biosynthetic proteins <i>pdxJ-pdxA</i>	<i>pdxAJ</i>	PHT + DX5P -> P5P + C02	2
Pyridoxine 5'-phosphate oxidase	<i>pdxH</i>	P5P + O2 -> PL5P + H2O2	1
Threonine synthase	<i>thrC</i>	PHT -> 4HLT + PI	1
Hypothetical Enzyme		4HLT -> PYRDX	0
Pyridoxine kinase	<i>pdxK</i>	PYRDX + ATP -> P5P + ADP	1
Hypothetical Enzyme		P5P -> PYRDX + PI	0
Hypothetical Enzyme		PL5P -> PL + PI	0
Pyridoxine kinase	<i>pdxK</i>	PL + ATP -> PL5P + ADP	1

Enzyme	Gene	Reaction	E. coli genome
Pyridoxine 5'-phosphate oxidase	<i>pdxH</i>	PYRDX + O ₂ <-> PL + H ₂ O ₂	1
Pyridoxine 5'-phosphate oxidase	<i>pdxH</i>	PL + O ₂ + NH ₃ <-> PDLA + H ₂ O ₂	1
Pyridoxine kinase	<i>pdxK</i>	PDLA + ATP -> PDLA5P + ADP	1
Hypothetical Enzyme		PDLA5P -> PDLA + PI	0
Pyridoxine 5'-phosphate oxidase	<i>pdxH</i>	PDLA5P + O ₂ -> PL5P + H ₂ O ₂ + NH ₃	1
Serine hydroxymethyltransferase (serine methylase)	<i>glyA</i>	PL5P + GLU -> PDLA5P + AKG	1
Serine hydroxymethyltransferase (serine methylase)	<i>glyA</i>	PL5P + ALA -> PDLA5P + PYR	1
Glutamine fructose-6-phosphate Transaminase	<i>glmS</i>	FBP + GLN -> GLU + GAGP	1
Phosphoglucosamine mutase	<i>glmM</i>	GAGP <-> GA1P	0
N-Acetylglucosamine-1-phosphate-uridylyltransferase	<i>glmU</i>	UTP + GA1P + ACCOA -> UDPNAG + PPI + COA	1
UDP-N-acetylglucosamine acyltransferase	<i>lpxA</i>	C14OACP + UDPNAG -> ACP + UDPG2AA	1
UDP-3-O-acyl-N-acetylglucosamine deacetylase	<i>lpxC</i>	UDPG2AA -> UDPG2A + AC	1
UDP-3-O-(3-hydroxymyristoyl)glucosamine-acyltransferase	<i>lpxD</i>	UDPG2A + C14OACP -> ACP + UDPG23A	1
UDP-sugar hydrolase	<i>ushA</i>	UDPG23A -> UMP + LIPX	1
Lipid A disaccharide synthase	<i>lpxB</i>	LIPX + UDPG23A -> UDP + DISAC1P	1
Tetraacyldisaccharide 4' kinase		DISAC1P + ATP -> ADP + LIPIV	0
3-Deoxy-D-manno-octulosonic-acid transferase (KDO transferase)	<i>ltdA</i>	LIPIV + CMPKDO -> KDOLIPIV + CMP	1
3-Deoxy-D-manno-octulosonic-acid transferase (KDO transferase)	<i>ltdA</i>	KDOLIPIV + CMPKDO -> K2LIPIV + CMP	1
Endotoxin synthase	<i>htrB, msbB</i>	K2LIPIV + C14OACP + C12OACP -> LIPA + 2 ACP	2

Enzyme	Gene	Reaction	E. coli genome
3-Deoxy-D-manno-octulosonic-acid 8-phosphate synthase	<i>kdsA</i>	PEP + ASF → KDO + P _i	1
3-Deoxy-D-manno-octulosonic-acid 8-phosphate phosphatase		KDO → KDO + P _i	0
CMP-2-keto-3-deoxyoctonate synthesis	<i>kdsB</i>	KDO + CTP → PPI + CMPKDO	1
ADP-L-glycero-D-mannoheptose 6-epimerase	<i>lpcA, rfaED</i>	S7P + ATP → ADPHEP + PPI	1
UDP-glucose-1-phosphate uridylyltransferase	<i>galU, galF</i>	G1P + UTP → PPI + UDPG	2
Ethanolamine phosphotransferase		PE + CMP <→ CDPETN + DGR	0
Phosphatidate phosphatase		PA → P _i + DGR	0
Diacylglycerol kinase	<i>dgkA</i>	DGR + ATP → ADP + PA	1
LPS Synthesis - truncated version of LPS (ref neid)	<i>rfaLJIGFC</i>	LPA + 3 ADPHEP + 2 UDPG + 2 CDPETN + 3 CMPKDO → LPS + 3 ADP + 2 UDP + 3 CMP + 2 CDP	6
UDP-N-acetylglucosamine-enolpyruvate transferase	<i>murA</i>	UDPNAG + PEP → UDPNAGEP + P _i	1
UDP-N-acetylglucosamine-enolpyruvate dehydrogenase	<i>murB</i>	UDPNAGEP + NADPH → UDPNAM + NADP	1
UDP-N-acetylmuramate-alanine ligase	<i>murC</i>	UDPNAM + ALA + ATP → ADP + P _i + UDPNAMA	1
UDP-N-acetylmuramoylalanine-D-glutamate ligase	<i>murD</i>	UDPNAMA + DGLU + ATP → UDPNAMAG + ADP + P _i	1
UDP-N-acetylmuramoylalanyl-D-glutamate 2,6-diaminopimelate ligase	<i>murE</i>	UDPNAMAG + ATP + MDAP → UNAGD + ADP + P _i	1
D-Alanine-D-alanine adding enzyme	<i>murF</i>	UNAGD + ATP + AA → UNAGDA + ADP + P _i	1
Glutamate racemase	<i>murI</i>	GLU <→ DGLU	1
D-alanine ligases	<i>ddlAB</i>	2 DALA <→ AA	2

Enzyme	Gene	Reaction	E. coli genome
Phospho-N-acetylmuramoyl pentapeptide transferase	<i>mraY</i>	UNAGDA → UMP + Pi + UNPTDD	1
N-Acetylglucosaminyl transferase	<i>murG</i>	UNPTDD + UDPNAG → UDP + PEPTDD	1
Arabinose (low affinity)	<i>araE</i>	ARABxt + HEXT <→ ARAB	1
Arabinose (high affinity)	<i>araFGH</i>	ARABxt + ATP → ARAB + ADP + Pi	3
Dihydroxyacetone		DHAXt + PEP → T3P2 + PYR	0
Fructose	<i>fruABF</i>	FRUxt + PEP → F1P + PYR	2
Fucose	<i>fucP</i>	FUCxt + HEXT <→ FUC	1
Galactitol	<i>galABC</i>	GLT1xt + PEP → GLT1P + PYR	3
Galactose (low affinity)	<i>galP</i>	GLACxt + HEXT → GLAC	1
Galactose (low affinity)	<i>galP</i>	GLCxt + HEXT → GLC	1
Galactose (high affinity)	<i>mg1ABC</i>	GLACxt + ATP → GLAC + ADP + Pi	3
Glucitol	<i>srlA1A2B</i>	GLT1xt + PEP → GLT6P + PYR	3
Gluconate	<i>gnrST</i>	GLCxt + ATP → GLCN + ADP + Pi	1
Glucose	<i>ptsG, crr</i>	GLCxt + PEP → G6P + PYR	2
Glycerol	<i>glpF</i>	GLxt <→ GL	1
Lactose	<i>lacY</i>	LCTSxt + HEXT <→ LCTS	1
Maltose	<i>malX, crr, malEFGK, lamB</i>	MLT1xt + PEP → MLT6P + PYR	7
Mannitol	<i>mtlA, cmt4B</i>	MNT1xt + PEP → MNT6P + PYR	3
Mannose	<i>manXYZ, ptsPAI</i>	MANxt + PEP → MAN1P + PYR	6
Melibiose	<i>melB</i>	MEL1xt + HEXT → MELI	1

Enzyme	Gene	Reaction	E. coli genome
N-Acetylglucosamine	<i>nagE, ptsH</i>	NAG + PEP -> NAGP + PYR	2
Rhamnose	<i>rhaT</i>	RMNxt + ATP -> RMN + ADP + PI	1
Ribose	<i>rbsABCD, xylH</i>	RIBxt + ATP -> RIB + ADP + PI	5
Sucrose	<i>scr</i>	SUCxt + PEP -> SUC6P + PYR	0
Trehalose	<i>treAB</i>	TRExt + PEP -> TRE6P + PYR	2
Xylose (low affinity)	<i>xylE</i>	XYLxt + HEXT -> XYL	1
Xylose (high affinity)	<i>xylFG, rbsB</i>	XYLxt + ATP -> XYL + ADP + PI	3
Alanine	<i>cycA</i>	ALAXt + ATP -> ALA + ADP + PI	1
Arginine	<i>argPMQJL, argT hisMOP</i>	ARGxt + ATP -> ARG + ADP + PI	9
Asparagine (low Affinity)		ASNxt + HEXT -> ASN	0
Asparagine (high Affinity)		ASNxt + ATP -> ASN + ADP + PI	0
Aspartate	<i>gltP</i>	ASPxt + HEXT -> ASP	1
Aspartate	<i>gltJKL</i>	ASPxt + ATP -> ASP + ADP + PI	3
Branched chain amino acid transport	<i>brnD</i>	BCAAXt + HEXT -> BCAA	1
Cysteine	<i>not identified</i>	CYSxt + ATP -> CYS + ADP + PI	0
D-Alanine	<i>cycA</i>	DALAXt + ATP -> DALA + ADP + PI	1
D-Alanine glycine permease	<i>cycA</i>	DALAXt + HEXT -> DALA	1
D-Alanine glycine permease	<i>cycA</i>	DSExt + HEXT -> DSER	1
D-Alanine glycine permease	<i>cycA</i>	GLYxt + HEXT -> GLY	1
Diaminopimelic acid		MDAPxt + ATP -> MDAP + ADP + PI	0
γ-Aminobutyrate transport	<i>gabP</i>	GABAXt + ATP -> GABA + ADP + PI	1

Enzyme	Gene	Reaction	E. coli genome
Glutamate	<i>gltP</i>	GLUxt + HEXT <-> GLU	1
Glutamate	<i>gltS</i>	GLUxt + HEXT <-> GLU	1
Glutamate	<i>gltJKL</i>	GLUxt + ATP -> GLU + ADP + Pi	3
Glutamine	<i>glnHPQ</i>	GLNxt + ATP -> GLN + ADP + Pi	3
Glycine	<i>cycA, proVWX</i>	GLYxt + ATP -> GLY + ADP + Pi	4
Histidine	<i>hisJMPQ</i>	HISxt + ATP -> HIS + ADP + Pi	4
Isoleucine	<i>livJ</i>	ILExt + ATP -> ILE + ADP + Pi	1
Leucine	<i>livHKM/livFGJ</i>	LEUxt + ATP -> LEU + ADP + Pi	6
Lysine	<i>lysP</i>	LYSxt + HEXT <-> LYS	1
Lysine	<i>argT, hisMPQ</i>	LYSxt + ATP -> LYS + ADP + Pi	4
Lysine/Cadaverine	<i>cadB</i>	LYSxt + ATP -> LYS + ADP + Pi	1
Methionine	<i>metD</i>	METxt + ATP -> MET + ADP + Pi	0
Ornithine	<i>argT, hisMPQ</i>	ORNxt + ATP -> ORN + ADP + Pi	4
Phenylalanine	<i>aroP/mtr/pheP</i>	PHExt + HEXT <-> PHE	3
Proline	<i>putP, proPWX</i>	PROxt + HEXT <-> PRO	4
Proline	<i>cycA, proVW</i>	PROxt + ATP -> PRO + ADP + Pi	4
Putrescine	<i>putEFHIG</i>	PTRCxt + ATP -> PTRC + ADP + Pi	5
Serine	<i>sdxC</i>	SERxt + HEXT <-> SER	1
Serine	<i>cycA</i>	SERxt + ATP -> SER + ADP + Pi	1
<u>Spermidine & putrescine</u>	<i>potABCD</i>	SPMDxt + ATP -> SPMD + ADP + Pi	4
<u>Spermidine & putrescine</u>	<i>potABCD</i>	PTRCxt + ATP -> PTRC + ADP + Pi	4

Enzyme	Gene	Reaction	E. coli genome
Threonine	<i>thrJ</i>	THRxt + ATP → THR + ADP + Pi	1
Threonine	<i>tdcC</i>	THRxt + HEXT ↔ THR	1
Tryptophan	<i>tnaB</i>	TRPxt + HEXT ↔ TRP	1
Tyrosine	<i>tyrP</i>	TYRxt + HEXT ↔ TYR	1
Valine	<i>livJ</i>	VALxt + ATP → VAL + ADP + Pi	1
Dipeptide	<i>dppABCD</i>	DIPEPxt + ATP → DIPEP + ADP + Pi	5
Dipeptide	<i>oppABCD</i>	DPEPxt + ATP → DPEP + ADP + Pi	5
Peptide	<i>sepABD</i>	PEPTxt + ATP → PEPT + ADP + Pi	3
Uracil	<i>uraA</i>	URAXt + HEXT → URA	1
Nicotinamide mononucleotide transporter	<i>pnuC</i>	NMNxt + HEXT → + NMN	1
Cytosine	<i>codB</i>	CYTSxt + HEXT → CYTS	1
Adenine	<i>purB</i>	ADxt + HEXT → AD	1
Guanine	<i>gpt, hpt</i>	GNxt ↔ GN	2
Hypoxanthine	<i>gpt, hpt</i>	HYXNxt ↔ HYXN	2
Xanthosine	<i>xapB</i>	XTSNxt ↔ XTSN	1
Xanthine	<i>gpt</i>	XANxt ↔ XAN	1
G-system	<i>nupG</i>	ADNxt + HEXT → ADN	1
G-system	<i>nupG</i>	GSNxt + HEXT → GSN	1
G-system	<i>nupG</i>	URIxt + HEXT → URI	1
G-system	<i>nupG</i>	CYTDxt + HEXT → CYTD	1
G-system (transports all nucleosides)	<i>nupG</i>	INSxt + HEXT → INS	1

Enzyme	Gene	Reaction	E. coli genome
G-system	<i>nupG</i>	XTSNxt + HEXT -> XTSN	1
G-system	<i>nupG</i>	DTxt + HEXT -> DT	1
G-system	<i>nupG</i>	DTNxt + HEXT -> DIN	1
G-system	<i>nupG</i>	DGxt + HEXT -> DG	1
G-system	<i>nupG</i>	DAxt + HEXT -> DA	1
G-system	<i>nupG</i>	DCxt + HEXT -> DC	1
G-system	<i>nupG</i>	DUxt + HEXT -> DU	1
C-system	<i>nupC</i>	ADNxt + HEXT -> ADN	1
C-system	<i>nupC</i>	URtxt + HEXT -> URI	1
C-system	<i>nupC</i>	CYTDxt + HEXT -> CYTD	1
C-system	<i>nupC</i>	DTxt + HEXT -> DT	1
C-system	<i>nupC</i>	DAxt + HEXT -> DA	1
C-system	<i>nupC</i>	DCxt + HEXT -> DC	1
C-system	<i>nupC</i>	DUxt + HEXT -> DU	1
Nucleosides and deoxynucleoside	<i>tsx</i>	ADNxt + HEXT -> ADN	1
Nucleosides and deoxynucleoside	<i>tsx</i>	GSNxt + HEXT -> GSN	1
Nucleosides and deoxynucleoside	<i>tsx</i>	URtxt + HEXT -> URI	1
Nucleosides and deoxynucleoside	<i>tsx</i>	CYTDxt + HEXT -> CYTD	1
Nucleosides and deoxynucleoside	<i>tsx</i>	INSxt + HEXT -> INS	1
Nucleosides and deoxynucleoside	<i>tsx</i>	XTSNxt + HEXT -> XTSN	1
Nucleosides and deoxynucleoside	<i>tsx</i>	DTxt + HEXT -> DT	1

Enzyme	Gene	Reaction	E. coli genome
Nucleosides and deoxynucleoside	<i>tsx</i>	DINxt + HEXT -> DIN	1
Nucleosides and deoxynucleoside	<i>tsx</i>	DGxt + HEXT -> DG	1
Nucleosides and deoxynucleoside	<i>tsx</i>	DAxt + HEXT -> DA	1
Nucleosides and deoxynucleoside	<i>tsx</i>	DCxt + HEXT -> DC	1
Nucleosides and deoxynucleoside	<i>tsx</i>	DUxt + HEXT -> DU	1
Acetate transport		ACxt + HEXT <-> AC	0
Lactate transport		LACxt + HEXT <-> LAC	0
L-Lactate	<i>lldP</i>	LLACxt + HEXT <-> LLAC	1
Formate transport	<i>focA</i>	FORxt <-> FOR	1
Ethanol transport		ETHxt + HEXT <-> ETH	0
Succinate transport	<i>dcuAB</i>	SUCCxt + HEXT <-> SUCC	2
Pyruvate transport		PYRxt + HEXT <-> PYR	0
Ammonia transport	<i>amtB</i>	NH3xt + HEXT <-> NH3	1
Potassium transport	<i>kdpABC</i>	Kxt + ATP -> K + ADP + Pi	3
Potassium transport	<i>trkAHEG</i>	Kxt + HEXT <-> K	3
Sulfate transport	<i>cysPTUWAZ, sbp</i>	SLFxt + ATP -> SLF + ADP + Pi	7
Phosphate transport	<i>pstABCS</i>	Plxt + ATP -> ADP + 2 Pi	4
Phosphate transport	<i>pitAB</i>	Plxt + HEXT <-> Pi	2
Glycerol-3-phosphate	<i>glpT, ugpABCE</i>	GL3Pxt + Pi -> GL3P	5
Dicarboxylates	<i>dcuAB, dclA</i>	SUCCxt + HEXT <-> SUCC	3
Dicarboxylates	<i>dcuAB, dclA</i>	FUMxt + HEXT <-> FUM	3

Enzyme	Gene	Reaction	E. coli genome
Dicarboxylates	<i>dcuAB, dctA</i>	MALxt + HEXT <-> MAL	3
Dicarboxylates	<i>dcuAB, dctA</i>	ASPrxt + HEXT <-> ASP	3
Fatty acid transport	<i>fadL</i>	C140xt -> C140	1
Fatty acid transport	<i>fadL</i>	C160xt -> C160	1
Fatty acid transport	<i>fadL</i>	C180xt -> C180	1
α -Ketoglutarate	<i>kgtP</i>	AKGxt + HEXT <-> AKG	1
Na/H antiporter	<i>nhaABC</i>	NAXt + <-> NA + HEXT	2
Na/H antiporter	<i>chaABC</i>	NAXt + <-> NA + HEXT	3
Pantothenate	<i>panF</i>	PNT0xt + HEXT <-> PNT0	1
Sialic acid permease	<i>nanT</i>	SLAXt + ATP -> SLA + ADP + PI	1
Oxygen transport		O2xt <-> O2	0
Carbon dioxide transport		CO2xt <-> CO2	0
Urea transport		UREAxt +2 HEXT <-> UREA	0
ATP drain flux for constant maintenance requirements		ATP -> ADP + PI	0
Glyceraldehyde transport	<i>gulP</i>	GLALxt <-> GLAL	0
Acetaldehyde transport		ACALxt <-> ACAL	0

Table 2

Comparison of the predicted mutant growth characteristics from the gene deletion study to published experimental results with single and double mutants.

Gene	Glucose (<i>in vivo</i> / <i>in silico</i>)	Glycerol (<i>in vivo</i> / <i>in silico</i>)	Succinate (<i>in vivo</i> / <i>in silico</i>)	Acetate (<i>in vivo</i> / <i>in silico</i>)
<i>aceEF</i>	-/+			
<i>aceA</i>				-/-
<i>aceB</i>				-/-
<i>ackA</i>				+/+
<i>acs</i>				+/+
<i>acn</i>	-/-	-/-	-/-	-/-
<i>cyd</i>	+/+			
<i>cyo</i>	+/+			
<i>eno</i>	-/+	-/+	-/-	-/-
<i>fba</i>	-/+			
<i>fbp</i>	+/+	-/-	-/-	-/-
<i>gap</i>	-/-	-/-	-/-	-/-
<i>glfA</i>	-/-	-/-	-/-	-/-
<i>gnd</i>	+/+			
<i>idh</i>	-/-	-/-	-/-	-/-
<i>ndh</i>	+/+	+/+		
<i>nuo</i>	+/+	+/+		
<i>pfk</i>	-/+			
<i>pgi</i>	+/+	+/+		
<i>pgk</i>	-/-	-/-	-/-	-/-
<i>pgl</i>	+/+			
<i>pntAB</i>	+/+	+/+	+/+	+/+
<i>glk</i>	+/+			
<i>ppc</i>	±/+	-/+	+/+	+/+
<i>pta</i>				+/+
<i>pts</i>	+/+			
<i>pyk</i>	+/+			
<i>rpi</i>	-/-	-/-	-/-	-/-
<i>sdhABCD</i>	+/+			
<i>tpi</i>	-/+	-/-	-/-	-/-

Gene	Glucose (<i>in vivo</i> <i>in silico</i>)	Glycerol (<i>in vivo</i> <i>in silico</i>)	Succinate (<i>in vivo</i> <i>in silico</i>)	Acetate (<i>in vivo</i> <i>in silico</i>)
<i>unc</i>	+ +		- -	- -
<i>zwf</i>	+ +			
<i>sucAD</i>	+ +			
<i>zwf, pnt</i>	+ +			
<i>pck, mez</i>			- -	- -
<i>pck, pps</i>			- -	- -
<i>pgi, zwf</i>	- -			
<i>pgi, gnd</i>	- -			
<i>pta, acs</i>				- -
<i>tktA, tktB</i>	- -			

Results are scored as + or - meaning growth or no growth determined from *in vivo* | *in silico* data. In 73 of 80 cases the *in silico* behavior is the same as the experimentally observed behavior.

WHAT IS CLAIMED IS:

1. A method for determining the genome specific stoichiometric matrix of an organism, comprising:
 providing the nucleotide sequence of a metabolic gene in the organism;
 identifying the open reading frame of the metabolic gene;
 assigning a function to the metabolic gene based on its nucleotide or amino acid homology to other,
 5 known metabolic genes;
 determining the metabolic genotype of the organism based on the assigned function of the
 metabolic gene; and
 determining the genome specific stoichiometric matrix for the organism.
2. The method of Claim 1, further comprising determining a phenotype of the organism.
- 10 3. The method of Claim 2, wherein determining the phenotype of the organism comprises analyzing
 the consequences of reduction or addition to the composition of the metabolic genotype.
4. The method of Claim 2, further comprising identifying lethal genetic deletions.
5. The method of Claim 4 further comprising determining the effectiveness of a drug through analysis
 of the lethal genetic deletions.
- 15 6. The method of Claim 1, further comprising determining the minimal media composition required to
 sustain growth of the organism.
7. The method of Claim 1, further comprising determining an optimal media composition for growing
 the organism.
8. The method of Claim 1, further comprising determining the most advantageous complement of
 20 genes in the organism necessary to sustain growth in a particular environmental condition.
9. The method of Claim 1, wherein the organism is *Escherichia Coli*.
10. The method of Claim 1, comprising the use of a Flux Based Analysis on the stoichiometric matrix.
11. The method of Claim 1, comprising adding biochemical information for a metabolic gene to the
 stoichiometric matrix.
- 25 12. A method for determining a potential genetic target for a drug that kills an organism, comprising:
 providing the nucleotide sequence of a metabolic gene in the organism;
 identifying the open reading frame of the metabolic gene;
 assigning a function to the metabolic gene based on its nucleotide or amino acid homology to other,
 known metabolic genes;
 30 determining whether the metabolic gene is required for growth of the organism;
 repeating the providing, identifying, assigning and determining steps for other metabolic genes of
 the organism; and
 selecting a gene that is required for growth of the organism as a target for the drug.
13. The method of Claim 12, wherein the organism is *Escherichia coli*.

14. The method of Claim 12, comprising performing a Flux Based Analysis of a stoichiometric matrix from the organism.
15. The method of Claim 12, comprising the use of biochemical information on the metabolic gene to determine whether it is required for growth of the organism.
- 5 16. A computer system comprising a memory having instructions that when executed perform the steps of:
- providing the nucleotide sequence of a metabolic gene in an organism;
- identifying the open reading frame of the metabolic gene;
- assigning a function to the metabolic gene based on its nucleotide or amino acid homology to other,
- 10 known metabolic genes;
- determining the metabolic genotype of the organism based on the assigned function of the unknown metabolic gene; and
- determining the genome specific stoichiometric matrix for the organism.
- 15 17. The computer system of Claim 16, wherein said memory is selected from the group consisting of: a hard disk, optical memory, Random Access Memory, Read Only Memory and Flash Memory.
18. The computer system of Claim 16, wherein said computer system is based on an Intel® microprocessor.
19. The computer system of Claim 16, wherein the organism is *Escherichia Coli*.
- 20 20. The computer system of Claim 16, further comprising instructions that when executed perform the method of identifying lethal genetic deletions for the organism.
21. The computer system of Claim 16, comprising instructions, that when executed, add biochemical information on a metabolic gene to the stoichiometric matrix.
22. A method for representing a living organism in a computer system, comprising:
- providing the nucleotide sequence of a metabolic gene in the organism;
- 25 identifying the open reading frame of the metabolic gene;
- assigning a function to the metabolic gene based on its nucleotide or amino acid homology to other,
- known metabolic genes;
- determining the metabolic genotype of the organism based on the assigned function of the metabolic gene;
- 30 determining the genome specific stoichiometric matrix for the organism; and
- storing the genome specific stoichiometric matrix in a memory of the computer.
23. The method of Claim 22, wherein the organism is *Escherichia coli*.
24. The method of Claim 22, comprising the use of Flux Based Analysis to analyze the stoichiometric matrix.
- 35 25. The method of Claim 22, comprising adding biochemical information on a metabolic gene to determine the metabolic genotype of the organism.

26. The method of Claim 22, comprising calculating the genome specific stoichiometric matrix using Flux Based Analysis.

27. A genome specific stoichiometric matrix representing the metabolism of a living organism, produced by a process comprising:

- 5 providing the nucleotide sequence of a metabolic gene in the organism;
 identifying the open reading frame of the metabolic gene;
 assigning a function to the metabolic gene based on its nucleotide or amino acid homology to other, known metabolic genes;
 determining the metabolic genotype of the organism based on the assigned function of the
10 metabolic gene; and
 determining the genome specific stoichiometric matrix for the organism.

28. The stoichiometric matrix of Claim 1, wherein the organism is *Escherichia Coli*.

29. The stoichiometric matrix of Claim 1, wherein the stoichiometric matrix is determined using Flux Based Analysis.

15 30. The stoichiometric matrix of Claim 1, produced by the process of adding biochemical information for the metabolic gene.

1/3




Figure 1





Figure 3



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 August 2000 (10.08.2000)

PCT

(10) International Publication Number
WO 00/46405 A3

(51) International Patent Classification⁷: C12Q 1/68,
G06F 19/00

(21) International Application Number: PCT/US00/02882

(22) International Filing Date: 2 February 2000 (02.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/243,022 2 February 1999 (02.02.1999) US

(71) Applicant and

(72) Inventor: PALSSON, Bernhard [US/US]; 730 Fern Glen,
La Jolla, CA 92037 (US).

(74) Agent: HUNT, Dale, C.; 16th Floor, 620 Newport Center
Drive, Newport Beach, CA 92660 (US).

(81) Designated States (national): AE, AL, AM, AT, AU (util-
ity model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,

CR, CU, CZ, CZ (utility model), DE, DE (utility model),
DK, DK (utility model), DM, EE, EE (utility model), ES,
FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:
10 May 2001

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 00/46405 A3

(54) Title: METHODS FOR IDENTIFYING DRUG TARGETS BASED ON GENOMIC SEQUENCE DATA

(57) Abstract: This invention provides a computational approach to identifying potential antibacterial drug targets based on a genome sequence and its annotation. Starting from a fully sequenced genome, open reading frame assignments are made which determine the metabolic genotype for the organism. The metabolic genotype, and more specifically its stoichiometric matrix, are analyzed using flux balance analysis to assess the effects of genetic deletions on the fitness of the organism and its ability to produce essential biomolecules required for growth.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/02882

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G06F19/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G06F C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EDWARDS JEREMY S ET AL: "How will bioinformatics influence metabolic engineering?" BIOTECHNOLOGY AND BIOENGINEERING, vol. 58, no. 2-3, 20 April 1998 (1998-04-20), pages 162-169, XP002153942 ISSN: 0006-3592 the whole document	1-30
X	TOMITA MASARU ET AL: "E-CELL: Software environment for whole-cell simulation." BIOINFORMATICS (OXFORD), vol. 15, no. 1, January 1999 (1999-01), pages 72-84, XP000961128 ISSN: 1367-4803 the whole document	1-30

-/--

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

27 November 2000

Date of mailing of the international search report

12/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Reuter, U

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 00/02882

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BONARIUS H P J ET AL: "Flux analysis of underdetermined metabolic networks: the quest for the missing constraints" TRENDS IN BIOTECHNOLOGY, GB, ELSEVIER PUBLICATIONS, CAMBRIDGE, vol. 15, no. 8, 1 August 1997 (1997-08-01), pages 308-314, XP004083358 ISSN: 0167-7799 the whole document ---	1-30
X	PALSSON: "What lies beyond bioinformatics?" NATURE BIOTECHNOLOGY, vol. 15, January 1997 (1997-01), pages 3-4, XP002153943 page 4 ---	1-30
X	SCHILLING CHRISTOPHE H ET AL: "The underlying pathway structure of biochemical reaction networks." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 8, 14 April 1998 (1998-04-14), pages 4193-4198, XP002153944 April 14, 1998 ISSN: 0027-8424 the whole document ---	1-30
X	ARIGONI ET AL: "A GENOME-BASED APPROACH FOR THE IDENTIFICATION OF ESSENTIAL BACTERIAL GENES" NATURE BIOTECHNOLOGY, US, NATURE PUBLISHING, vol. 16, no. 9, September 1998 (1998-09), pages 851-856, XP002119419 ISSN: 1087-0156 the whole document ---	12, 13
X	BALTZ ET AL: "DNA sequence sampling of the Streptococcus pneumoniae genome to identify novel targets for antibiotic development" MICROBIAL DRUG RESISTANCE, US, LIEBERT, vol. 4, no. 1, 21 March 1998 (1998-03-21), pages 1-9, XP002112153 ISSN: 1076-6294 the whole document ---	12, 13

-/--

INTERNATIONAL SEARCH REPORT

Intern: al Application No

PCT/US 00/02882

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PRAMANIK J ET AL: "Stoichiometric model of Escherichia coli metabolism: Incorporation of growth-rate dependent biomass composition and mechanistic energy requirements." BIOTECHNOLOGY AND BIOENGINEERING, vol. 56, no. 4, 1997, pages 398-421, XP002153946 ISSN: 0006-3592 the whole document ---	27-30
X	SAUER UWE ET AL: "Metabolic capacity of Bacillus subtilis for the production of purine nucleosides, riboflavin, and folic acid." BIOTECHNOLOGY AND BIOENGINEERING, vol. 59, no. 2, 20 July 1998 (1998-07-20), pages 227-238, XP002153947 ISSN: 0006-3592 the whole document ---	27-30
A	KARP PETER D ET AL: "EcoCyc: Encyclopedia of Escherichia coli genes and metabolism." NUCLEIC ACIDS RESEARCH, vol. 25, no. 1, 1997, pages 43-50, XP002153948 ISSN: 0305-1048 the whole document ---	1-30
A	KARP P D: "Metabolic databases" TIBS TRENDS IN BIOCHEMICAL SCIENCES, EN, ELSEVIER PUBLICATION, CAMBRIDGE, vol. 23, no. 3, 1 March 1998 (1998-03-01), pages 114-116, XP004111317 ISSN: 0968-0004 the whole document ---	1-30
A	GALPERIN M Y ET AL: "Using metabolic pathway databases for functional annotation" TRENDS IN GENETICS, NL, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 8, 1 December 1998 (1998-12-01), pages 332-333, XP004131498 ISSN: 0168-9525 the whole document ---	1-30

-/--

INTERNATIONAL SEARCH REPORT

Intern: ;al Application No

PCT/US 00/02882

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	XIE L ET AL: "Integrated approaches to the design of media and feeding strategies for fed-batch cultures of animal cells" TRENDS IN BIOTECHNOLOGY,GB,ELSEVIER PUBLICATIONS, CAMBRIDGE, vol. 15, no. 3, 1 March 1997 (1997-03-01), pages 109-113, XP004054783 ISSN: 0167-7799 the whole document ---	1,6,7
X,P	SCHILLING CHRISTOPHE H ET AL: "Toward metabolic phenomics: Analysis of genomic data using flux balances." BIOTECHNOLOGY PROGRESS, vol. 15, no. 3, May 1999 (1999-05), pages 288-295, XP000961124 ISSN: 8756-7938 the whole document -----	1-30